<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54493</article-id><article-id pub-id-type="doi">10.7554/eLife.54493</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of <italic>Cx3cr1</italic></article-title></title-group><contrib-group><contrib contrib-type="author" id="author-170205"><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170206"><name><surname>Ibáñez</surname><given-names>Lidia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170207"><name><surname>Ciucci</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-182749"><name><surname>Halper</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170208"><name><surname>Rouleau</surname><given-names>Matthieu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0075-9880</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170209"><name><surname>Boutin</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170210"><name><surname>Hue</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30308"><name><surname>Duroux-Richard</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37844"><name><surname>Apparailly</surname><given-names>Florence</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170211"><name><surname>Garchon</surname><given-names>Henri-Jean</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30858"><name><surname>Wakkach</surname><given-names>Abdelilah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-168556"><name><surname>Blin-Wakkach</surname><given-names>Claudine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2621-3907</contrib-id><email>claudine.BLIN@unice.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Laboratoire de PhysioMédecine Moléculaire, CNRS</institution><addr-line><named-content content-type="city">Nice</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution>Université Côte d’Azur</institution><addr-line><named-content content-type="city">Nice</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution>Department of Pharmacy, Cardenal Herrera-CEU University</institution><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff><aff id="aff4"><label>4</label><institution>Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation</institution><addr-line><named-content content-type="city">Montigny-Le-Bretonneux</named-content></addr-line><country>France</country></aff><aff id="aff6"><label>6</label><institution>IRMB, Univ Montpellier, INSERM, CHU Montpellier</institution><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff><aff id="aff7"><label>7</label><institution>Genetics division, Ambroise Paré Hospital, AP-HP</institution><addr-line><named-content content-type="city">Boulogne-Billancourt</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Vunjak-Novakovic</surname><given-names>Gordana</given-names></name><role>Reviewing Editor</role><aff><institution>Columbia University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cheah</surname><given-names>Kathryn Song Eng</given-names></name><role>Senior Editor</role><aff><institution>The University of Hong Kong</institution><country>Hong Kong</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>05</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e54493</elocation-id><history><date date-type="received" iso-8601-date="2019-12-16"><day>16</day><month>12</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-04-26"><day>26</day><month>04</month><year>2020</year></date></history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54493-v1.pdf"/><abstract><p>Bone destruction relies on interactions between bone and immune cells. Bone-resorbing osteoclasts (OCLs) were recently identified as innate immune cells activating T cells toward tolerance or inflammation. Thus, pathological bone destruction not only relies on increased osteoclast differentiation, but also on the presence of inflammatory OCLs (i-OCLs), part of which express <italic>Cx3cr1</italic>. Here, we investigated the contribution of mouse Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs to bone loss. We showed that Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs differ considerably in transcriptional and functional aspects. Cx3cr1<sup>neg</sup> i-OCLs have a high ability to resorb bone and activate inflammatory CD4<sup>+</sup> T cells. Although Cx3cr1<sup>+</sup> i-OCLs are associated with inflammation, they resorb less and have in vitro an immune-suppressive effect on Cx3cr1<sup>neg</sup> i-OCLs, mediated by PD-L1. Our results provide new insights into i-OCL heterogeneity. They also reveal that different i-OCL subsets may interact to regulate inflammation. This contributes to a better understanding and prevention of inflammatory bone destruction.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>osteoclast</kwd><kwd>osteoporosis</kwd><kwd>osteoimmunology</kwd><kwd>bone destruction</kwd><kwd>inflammation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-16-CE14-0030</award-id><principal-award-recipient><name><surname>Apparailly</surname><given-names>Florence</given-names></name><name><surname>Garchon</surname><given-names>Henri-Jean</given-names></name><name><surname>Blin-Wakkach</surname><given-names>Claudine</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-15-IDEX-01</award-id><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name><name><surname>Blin-Wakkach</surname><given-names>Claudine</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002915</institution-id><institution>Fondation pour la Recherche Médicale</institution></institution-wrap></funding-source><award-id>ECO20160736019</award-id><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008319</institution-id><institution>Fondation Arthritis</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name><name><surname>Blin-Wakkach</surname><given-names>Claudine</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Société Française de Biologie des TissusMinéralisés</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013541</institution-id><institution>European Calcified Tissue Society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>American Society of Bone and Mineral Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>Intramural Research Program</award-id><principal-award-recipient><name><surname>Ciucci</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Osteoclasts emerging in inflammation are heterogeneous and encompass a strongly inflammatory subset with a high resorbing activity and an immune suppressive subset that are able to control each other.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Chronic inflammation and bone destruction are frequently associated due to complex interactions between activated immune cells and progenitors of bone-resorbing osteoclasts (OCLs). While they have long been attributed to the sole effect of immune cells on osteoclastogenesis, recent evidences demonstrated that these interactions are reciprocal (<xref ref-type="bibr" rid="bib7">Buchwald et al., 2012</xref>; <xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Kiesel et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Li et al., 2010</xref>). Indeed, OCLs are monocytic cells responding to immune signals and beside bone resorption, they present antigens and activate T cells (<xref ref-type="bibr" rid="bib31">Madel et al., 2019</xref>). However, to date, the mechanisms that reciprocally link inflammation and bone destruction remain poorly understood.</p><p>OCLs are long-lived multinucleated cells arising from bone marrow (BM) progenitors (<xref ref-type="bibr" rid="bib4">Arai et al., 1999</xref>; <xref ref-type="bibr" rid="bib21">Jacome-Galarza et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Jacome-Galarza et al., 2019</xref>). However, in inflammation, they also arise from inflammatory Ly6C<sup>hi</sup> monocytes (MNs) (<xref ref-type="bibr" rid="bib1">Ammari et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Seeling et al., 2013</xref>) and dendritic cells (DCs) including in vivo (<xref ref-type="bibr" rid="bib55">Wakkach et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib33">Mansour et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Rivollier et al., 2004</xref>; <xref ref-type="bibr" rid="bib31">Madel et al., 2019</xref>). Furthermore, OCLs permanently fuse with MNs and undergo fission to maintain their nuclei number (<xref ref-type="bibr" rid="bib22">Jacome-Galarza et al., 2019</xref>). We and others showed that depending on their origin and environment, OCLs induce different T cell responses. In steady state or when derived from BM MNs of healthy mice, OCLs activate regulatory CD4<sup>+</sup> and CD8<sup>+</sup> T cells (tolerogenic-OCLs/t OCLs) (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Kiesel et al., 2009</xref>), whereas when derived from DCs or during inflammation, they induce TNFα-producing CD4<sup>+</sup> T cells (inflammatory-OCLs/i-OCLs) (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Madel et al., 2019</xref>). Thus, according to their origin and environment, OCLs are heterogeneous and initiate different immune responses. However, the full contribution of i-OCLs to inflammatory bone loss remains to be elucidated.</p><p>Recently, we identified the fractalkine receptor Cx3cr1 as a marker identifying i-OCLs (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). Cx3cr1 is expressed by OCL precursors and mediates their BM recruitment by Cx3cl1-producing endothelial cells and osteoblasts (<xref ref-type="bibr" rid="bib17">Han et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Hasegawa et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Koizumi et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Matsuura et al., 2017</xref>). During osteoclastogenesis, the level of expression of <italic>Cx3cr1</italic> decreases and is very low in t-OCLs (<xref ref-type="bibr" rid="bib19">Hoshino et al., 2013</xref>; <xref ref-type="bibr" rid="bib25">Koizumi et al., 2009</xref>). However, in inflammatory conditions, <italic>Cx3cr1</italic> remains expressed in about 25% of i-OCLs (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). Nevertheless, the role of Cx3cr1 in i-OCLs as well as the function and contribution of Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> i-OCLs in inflammation have not yet been explored.</p><p>We addressed these questions using <italic>Cx3cr1</italic><sup>GFP</sup> mutant mice in which the <italic>Gfp</italic> gene is inserted in the second exon of the <italic>Cx3cr1</italic> gene (<xref ref-type="bibr" rid="bib23">Jung et al., 2000</xref>). Consequently, while Cx3cr1 activity is normal in wild type (WT) <italic>Cx3cr1</italic><sup>GFP/+</sup> mice, this protein is non-functional in <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice and in both mice, GFP expression allows to identify Cx3cr1-expressing cells (<xref ref-type="bibr" rid="bib23">Jung et al., 2000</xref>). We evaluated the consequences of <italic>Cx3cr1</italic> deficiency on inflammatory bone loss in vivo in ovariectomized (OVX) mice, a model where osteoclastogenesis is driven by TNF-α and RANK-L-producing CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib9">Cenci et al., 2000</xref>; <xref ref-type="bibr" rid="bib28">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Weitzmann and Pacifici, 2006</xref>). These conditions are similar to those priming Cx3cr1<sup>+</sup> OCLs previously described in inflammatory colitis (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). We also compared Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs as well as <italic>Cx3cr1</italic>-deficient i-OCLs by RNA-sequencing (RNA-seq) analysis and in vitro functional assays. We showed that Cx3cr1 deficiency does not change the bone resorption and T cell activation capacity of mature Cx3cr1<sup>+</sup> i-OCLs demonstrating that the Cx3cr1 protein per se does not play a major role in these functions. Furthermore, we showed that Cx3cr1 is a marker that identifies two distinct subsets of i-OCLs (Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup>) having different immune functions. Our findings unveil the heterogeneity of i-OCLs and their contribution to inflammation and bone loss. These new insights into osteoimmunology and OCL heterogeneity contribute to a better understanding of the bone microenvironment regulation and the underlying molecular processes during inflammatory bone destruction.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Cx3cr1 deficiency protects against inflammatory bone loss in osteoporosis</title><p>We addressed in vivo the participation of Cx3cr1 in inflammatory osteoclastogenesis in ovariectomized (OVX) mice. We previously showed that Cx3cr1<sup>+</sup> i-OCLs increased in inflammatory colitis associated with bone destruction (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>) and we confirmed here that they also increased after ovariectomy in WT OVX mice (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To evaluate the implication of Cx3cr1 in OVX-induced bone loss, we used Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> and WT <italic>Cx3cr1</italic><sup>GFP/+</sup> control mice. Micro-CT analysis revealed that after ovariectomy, Cx3cr1-deficient mice displayed moderate but significant higher BV/TV and trabecular number and lower trabecular separation than WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>). They also had less TRAcP<sup>+</sup> OCLs compared to OVX WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Thus, Cx3cr1 deficiency partially protects against bone destruction in OVX mice.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Cx3cr1</italic>-deficient mice display reduced bone loss after ovariectomy.</title><p>(<bold>A</bold>) FACS analysis of Cx3cr1<sup>+</sup> OCLs generated from BM cells from SHAM-operated and OVX WT mice. Histograms indicate the mean ± SD percentage of Cx3cr1<sup>+</sup> i-OCLs (n = 4–5). (<bold>B</bold>) Representative images of femur µCT analysis from SHAM-operated and OVX WT <italic>Cx3cr1</italic><sup>GFP/+</sup> and Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice 6 weeks post-surgery. (<bold>C</bold>) Histograms show the mean ± SD percentage of bone volume fraction (BV/TV), trabecular number and trabecular separation (n = 8 mice per group). (<bold>D</bold>) Representative TRAcP staining on femora from OVX Cx3cr1<sup>GFP/+</sup> and Cx3cr1<sup>GFP/GFP</sup> mice. Scale bar = 100 µm. (<bold>E</bold>) Ex vivo FACS analysis of CD11c<sup>+</sup> DCs and (<bold>F</bold>) CD11b<sup>+</sup>Ly6C<sup>hi</sup> MNs present in the BM of SHAM and OVX mice. Cells were gated as in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and histograms are showing the absolute cell number of these populations in the bone marrow. **p&lt;0.01; ***p&lt;0.001; n.s., no significant difference.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Analysis of i-OCLs progenitors in OVX mice.</title><p>(<bold>A</bold>) Schematic representation of the differentiation of OCLs from blood CD11b<sup>+</sup>Ly6C<sup>hi</sup> monocytes from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice (<bold>B</bold>) FACS analysis on these CD11b<sup>+</sup> Ly6C<sup>hi</sup> MNs-derived OCLs using Hoechst 33342-A staining revealed that GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) OCLs differentiate efficiently from CD11b<sup>+</sup> Ly6C<sup>hi</sup> MNs. OCLs were gated as cells having three nuclei and more (≥3N) as described previously (<xref ref-type="bibr" rid="bib30">Madel et al., 2018</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Gating strategy for ex vivo FACS analysis.</title><p>Gating strategy for ex vivo FACS analysis of bone marrow DCs and inflammatory monocytes in SHAM and OVX mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig1-figsupp2-v1.tif"/></fig></fig-group><p>As Cx3cr1 is involved in the recruitment of OCL progenitors to the BM particularly under inflammatory conditions (<xref ref-type="bibr" rid="bib10">Charles et al., 2012</xref>), we examined i-OCL progenitors in the BM of OVX Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice and WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. While both DCs and Ly6C<sup>hi</sup> MNs have been involved in the formation of OCLs in pathological conditions, only DCs were shown to give rise to Cx3cr1<sup>+</sup> i-OCLs (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). Thus, we analyzed the osteoclastogenic capacity of blood Ly6C<sup>hi</sup> MNs sorted from <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. About 35% of the resulting OCLs expressed GFP indicating that Ly6C<sup>hi</sup> MNs are also progenitors of Cx3cr1<sup>+</sup> OCLs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–B</xref>). FACS analysis in OVX mice revealed that both DCs and Ly6C<sup>hi</sup> MNs increased in the BM of OVX <italic>Cx3cr1</italic><sup>GFP/+</sup> but not <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1E–F</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). These results suggest that the reduced bone loss observed in Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice is, at least partly, related to a decrease in BM progenitors of Cx3cr1<sup>+</sup> OCLs, namely DCs and Ly6C<sup>hi</sup> MNs.</p></sec><sec id="s2-2"><title>Cx3cr1 deficiency does not alter immune and bone resorption function of Cx3cr1<sup>+</sup> i-OCLs</title><p>These results suggest a central role of Cx3cr1 in i-OCL differentiation. To further investigate underlying mechanisms, we performed the first comparative RNA-seq approach on GFP<sup>+</sup> mature i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> and Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). OCLs represent a small population of cells firmly attached to the bone that cannot be isolated ex vivo in sufficient number for transcriptomic and functional assays (<xref ref-type="bibr" rid="bib30">Madel et al., 2018</xref>). Thus, i-OCLs were differentiated from BM-derived CD11c<sup>+</sup> DCs of WT <italic>Cx3cr1</italic><sup>GFP/+</sup> and Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice as described (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). Mature Cx3cr1<sup>+</sup> i-OCLs were then sorted based on their GFP expression and multinucleation according to <xref ref-type="bibr" rid="bib30">Madel et al. (2018)</xref> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Cx3cr1 deficiency does not affect resorption and immune function in Cx3cr1<sup>+</sup> i-OCLs.</title><p>(<bold>A</bold>) Schematic representation of the differentiation of i-OCLs from BM-derived DCs of WT <italic>Cx3cr1</italic><sup>GFP/+</sup> and Cx3cr-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice. (<bold>B</bold>) RNA-seq analysis on sorted GFP<sup>+</sup> i-OCLs (representing Cx3cr1<sup>+</sup> i-OCLs) differentiated from BM-derived DCs of WT <italic>Cx3cr1</italic><sup>GFP/+</sup> and Cx3cr-1deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice (gated as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Volcano-plot indicates –Log<sub>10</sub> adjusted p value versus log<sub>2 </sub>fold-change comparing gene expression in i-OCL subsets. (<bold>C</bold>) Matrix dissolution activity of sorted GFP<sup>+</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> and Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice seeded at the same cell density on a calcified matrix was evidence by red alizarin staining of the mineralized matrix. Unstained areas correspond to the resorbed areas. Left panel: representative images of resorbed area. Scale bar = 100 µm. Right panel: quantification of resorbed areas presented as mean ± SD percentage of three independent biological replicates each in triplicates. (<bold>D</bold>) FACS analysis of fluorescent-OVA uptake among GFP<sup>+</sup> i-OCLs from <italic>Cx3cr1</italic><sup>GFP/+</sup> and <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice. Left panel: representative density plots and right panel: percentage of OVA<sup>+</sup> cells from five independent experiments. (<bold>E</bold>) FACS analysis of GFP<sup>+</sup> i-OCLs from <italic>Cx3cr1</italic><sup>GFP/+</sup> and <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice in at least four independent experiments. (<bold>F</bold>) T cell proliferation assay on CD4<sup>+</sup> T cells labelled with CFSE and cultured in the presence of OVA-challenged GFP<sup>+</sup> i-OCLs differentiated from <italic>Cx3cr1</italic><sup>GFP/+</sup> and <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice and analyzed by FACS after 4 days of coculture. (<bold>G</bold>) CD4<sup>+</sup> T cells activated by OVA-challenged GFP<sup>+</sup> i-OCLs from <italic>Cx3cr1</italic><sup>GFP/+</sup> and <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice were analyzed for their expression of TNFα and IFNγ by FACS after intracytoplasmic staining of these cytokines. n.s., no significant difference.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Gating strategy for mature Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs.</title><p>(<bold>A</bold>) Gating strategy for the analysis and sorting of mature GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs using flow cytometry. After gating on total cells, doublets were excluded and cells with ≥3 nuclei (≥3N) cells were considered as OCLs and distinguished from 1 to 2 nucleated (1–2N) cells based on their Hoechst 33342 staining level. OCLs were analyzed based on their GFP expression and GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs were sorted.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Comparative transcriptomic analysis of Cx3cr1<sup>+</sup> i-OCLs from <italic>Cx3cr1</italic><sup>GFP/GFP</sup> and <italic>Cx3cr1</italic><sup>GFP/+</sup> mice.</title><p>(<bold>A</bold>) Comparative RNA-seq analysis between GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) i-OCLs from KO <italic>Cx3cr1</italic><sup>GFP/GFP</sup> and WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. Heatmap visualization of the z-scored expression for selected genes involved in OCL differentiation, T cell stimulation and antigen presentation. (<bold>B</bold>) Relative mRNA expression of GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) i-OCLs from KO <italic>Cx3cr1</italic><sup>GFP/GFP</sup> and WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. Results are represented as the mean with 95% confidence interval of three independent biological replicates conducted in triplicates. n.s., no significant difference.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig2-figsupp2-v1.tif"/></fig></fig-group><p>Except for their <italic>Cx3cr1</italic> expression, no differences were detected between GFP<sup>+</sup> i-OCLs from Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/+</sup> and WT <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice suggesting that Cx3cr1 deficiency did not change the identity of i-OCLs (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–B</xref>). Similarly, functional in vitro assays revealed that regardless if they derived from Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/+</sup> or WT <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice, GFP<sup>+</sup> i-OCLs had equivalent resorption activity, antigen-presentation capacity or expression of MHC-II and co-stimulatory molecules (<xref ref-type="fig" rid="fig2">Figure 2C–E</xref>). In addition, we performed a T cell activation assay using carboxyfluorescein succinimidyl ester (CFSE)-labelled CD4<sup>+</sup> T cells from OT-II mice bearing a T cell receptor (TCR) specific for the immunodominant ovalbumin (OVA) peptide (<xref ref-type="bibr" rid="bib5">Barnden et al., 1998</xref>). No differences between GFP<sup>+</sup> i-OCLs from <italic>Cx3cr1</italic><sup>GFP/GFP</sup> versus <italic>Cx3cr</italic>1<sup>GFP/+</sup> mice were found in their T cell activation and polarization capacity (<xref ref-type="fig" rid="fig2">Figure 2F–G</xref>). Thus, our results indicate that the function of the Cx3xr1 protein per se is not essential for the resorption and immune function of mature <italic>Cx3cr1</italic>-expressing i-OCLs.</p></sec><sec id="s2-3"><title>Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs are distinct populations</title><p>Although Cx3cr1 is important for i-OCL progenitors, its deficiency does not affect bone resorption or T cell activation by mature Cx3cr1-expressing i-OCLs. However, being expressed in part of i-OCLs, Cx3cr1 remains a marker for the heterogeneity of these i-OCLs. We explored this heterogeneity and in particular the specific role of Cx3cr1-expressing and Cx3cr1<sup>neg</sup> i-OCL subsets, comparing them using an RNA-seq approach. Mature Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs were generated in vitro from BM-derived CD11c<sup>+</sup> DCs of WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice and sorted based on their GFP expression and multinucleation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib30">Madel et al., 2018</xref>). A total of 1771 genes were significantly differentially expressed (adj.pVal &lt;0.05, Log<sub>2</sub>FC ≥ 1) between the 2 populations. Principal Component Analysis (PCA) of all detectable genes revealed that Cx3cr1<sup>+</sup> (GFP<sup>+</sup>) and Cx3cr1<sup>neg</sup> (GFP<sup>neg</sup>) i-OCLs were clustered into 2 distinct populations (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), which was reinforced by volcano plot and hierarchical clustering analysis of the top 107 significantly differently expressed genes (adj.pVal &lt;0.05 and Log<sub>2</sub>FC ≥ 1) (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>). In addition to <italic>Cx3cr1</italic>, genes interacting with its functional pathway were also differentially expressed (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). In particular, <italic>Nr1d1</italic>, a negative regulator of <italic>Cx3cr1</italic> (<xref ref-type="bibr" rid="bib49">Song et al., 2018</xref>) was reduced whereas <italic>Tlr4</italic> that mediates <italic>Cx3cr1</italic> upregulation by LPS (<xref ref-type="bibr" rid="bib39">Panek et al., 2015</xref>) was increased in Cx3cr1<sup>+</sup> versus Cx3cr1<sup>neg</sup> i-OCLs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B–C</xref>). These data suggest that <italic>Cx3cr1</italic> expression is tightly controlled during i-OCL differentiation. This was further confirmed by showing that Cx3cr1<sup>+</sup> OCLs could be generated from either Cx3cr1<sup>+</sup> or Cx3cr1<sup>neg</sup> BM-derived DCs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Thus, the expression of <italic>Cx3cr1</italic> in i-OCLs is not only inherited from their progenitors but may be acquired through a dynamic up-regulation during the differentiation of a subset of i-OCLs having a specific function. In particular, genes and functional pathways differentially expressed between Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs (<xref ref-type="fig" rid="fig3">Figure 3D–E</xref>) strongly suggested that the function of Cx3cr1<sup>+</sup> i-OCLs is related to the immune system. Therefore, we further characterized Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs focusing on their bone resorption capacity and their immune potential.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Transcriptomic profiling of Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs reveals two distinct populations of i-OCLs.</title><p>(<bold>A</bold>) Schematic representation of the differentiation of GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs from BM-derived DCs of WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice and their sorting (gated as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). (<bold>B</bold>) Principal component analysis of Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs clusters samples in two groups (red: GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) OCLs and blue GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) OCLs, both from <italic>Cx3cr1</italic><sup>GFP/+</sup> mice). Data shows the two first components on the top 500 most differentially expressed genes after batch correction. Each dot represents the expression profile of one sample. (<bold>C</bold>) Volcano-plot showing representative differentially expressed genes for Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs. Cut-off values were defined by a fold change (FC) &gt;2 and an adjusted p-value&lt;0.05. (<bold>D</bold>) Heatmap visualization of the top 107 genes significantly differentially expressed between GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs from <italic>Cx3cr1</italic><sup>GFP/+</sup> mice (adjusted p-value&lt;0.05, FC ≥2). (<bold>E</bold>) Graphical representation of gene ontology analysis associated with differentially expressed genes between Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs differ in their expression of Cx3cr1-interacting genes.</title><p>(<bold>A</bold>) Heatmap visualization of selected genes involved in the Cx3cr1 pathway that are significantly differentially expressed (p&lt;0.05, FC ≥2) between GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs differentiated from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. (<bold>B</bold>) Relative expression levels of <italic>Nr1d1</italic> and (<bold>C</bold>) <italic>Tlr4</italic> in Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs. (<bold>D</bold>) BM-derived DCs from <italic>Cx3cr1</italic><sup>GFP/+</sup> mice were sorted based on their expression of GFP and were differentiated into i-OCLs. Both GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) DCs gave rise to approx. 20% of Cx3cr1<sup>+</sup> i-OCLs. *p&lt;0.05; ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Transcriptomic profiling revealed that Cx3cr1<sup>neg</sup> i-OCLs expressed higher levels of genes responsible for bone resorption (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), which was confirmed by RT-qPCR (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We compared Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> i-OCLs subsets to CD169<sup>+</sup>CD68<sup>+</sup> macrophages that also express Cx3cr1 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>). Our results revealed that both Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> i-OCL subsets differed from BM-derived macrophages as they did not express CD68 and CD169 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C–D</xref>). Moreover, the 2 i-OCLs subsets shared the main characteristics of OCLs, e.g. TRAcP expression and resorption activity (<xref ref-type="fig" rid="fig4">Figure 4C–F</xref>) while BM-macrophages did not express TRAcP (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). However, when sorted mature Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> i-OCLs were seeded at the same cell concentration, Cx3cr1<sup>neg</sup> i-OCLs showed a higher matrix dissolution activity compared to Cx3cr1<sup>+</sup> i-OCLs (<xref ref-type="fig" rid="fig4">Figure 4E–F</xref>). These results demonstrate that Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> subsets correspond to 2 subsets of <italic>bona fide</italic> OCLs that differ in their resorption activity.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> i-OCLs differ in their resorbing activity.</title><p>(<bold>A</bold>) Heatmap visualization of the z-scored expression for selected genes involved in bone resorption, osteoclast fusion and differentiation that are differentially expressed between GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs both differentiated from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice (adjusted p-value&lt;0.05, FC ≥2). (<bold>B</bold>) RT-qPCR analysis on GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs. Results are represented as the mean with 95% confidence interval of 3 independent biological replicates in triplicates. (<bold>C</bold>) Flow cytometry analysis of TRAcP expression using ELF95 substrate in the 2 i-OCLs subsets. Percentage of positive cells (dark curve) compared to the negative control (light curve) is indicated. (<bold>D</bold>) Quantification of the mean fluorescence intensity (MFI) of TRAcP in GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs (n = 3). (<bold>E</bold>) Representative images of matrix dissolution activity of sorted GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs seeded at the same cell density. Red alizarin staining of the mineralized matrix revealed the resorbed areas as unstained. Scale bar = 100 µm. (<bold>F</bold>) Quantification of resorbed areas from three independent experiments in triplicates are indicated as percentage. ****p&lt;0.0001; n.s., no significant difference.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Cx3cr1<sup>+</sup> i-OCLs differ from Cx3cr1<sup>+</sup> BM-derived macrophages.</title><p>(<bold>A</bold>) Schematic representation of the differentiation of macrophages from the BM of <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. (<bold>B</bold>) FACS analysis of macrophage markers on BM-derived macrophages and (<bold>C</bold>) on GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs (n = 3). (<bold>D</bold>) Quantification of CD68<sup>+</sup>CD169<sup>+</sup> cells in Cx3cr1<sup>+</sup> BM-derived macrophages and in Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> i-OCL subsets. (<bold>E</bold>) Representative images of TRAcP staining on i-OCLs and BM-derived macrophages showing that contrasting to i-OCLs that all express TRAcP, BM-derived macrophages are negative for TRAcP expression. Scale bar = 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Besides these differences in bone resorption, RNA-seq data revealed significant differences in genes involved in antigen-processing and presentation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Further in vitro analysis confirmed that whereas both i-OCL subsets engulfed OVA, this capacity was significantly decreased in Cx3cr1<sup>neg</sup> i-OCLs (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>). In line with the RNA-seq data, FACS analysis confirmed that MHC-II molecules were more expressed in Cx3cr1<sup>neg</sup> than Cx3cr1<sup>pos</sup> i-OCLs (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), while no significant differences were observed in the expression of CD80 and CD86 (<xref ref-type="fig" rid="fig5">Figure 5E–F</xref>). Moreover, Cx3cr1<sup>neg</sup> i-OCLs showed higher capacity to induce T cell proliferation than Cx3cr1<sup>+</sup> i-OCLs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Nevertheless, both i-OCL subsets were able to induce TNFα and IFNγ-producing CD4<sup>+</sup> T cells but not FoxP3<sup>+</sup>CD4<sup>+</sup> regulatory T (Treg) cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), in accordance with the previously described immune properties of i-OCLs (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> subsets differ in their antigen uptake and presentation.</title><p>(<bold>A</bold>) Heatmap visualization of the z-scored expression for selected genes involved in antigen uptake, processing and presentation that are differentially expressed between GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice (adjusted pVal &lt;0.05, FC ≥2). (<bold>B</bold>) Representative FACS plots of OVA uptake in Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs. (<bold>C</bold>) Quantification of FACS analysis for OVA uptake in GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs (n = 5). (<bold>D–F</bold>) FACS analysis of GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs for (<bold>D</bold>) MHC-II, (<bold>E</bold>) CD80 and (<bold>F</bold>) CD86 (n = 6). (<bold>G</bold>). Representative FACS histograms for T cell proliferation assay of CFSE-labelled CD4<sup>+</sup> T cells from OT-II mice cultured with OVA-loaded GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) or GFP <sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs after 5 days of coculture. **p&lt;0.01; n.s., no significant difference.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>CD4<sup>+</sup> T cell polarization analysis CD4<sup>+</sup> T cells from OT-II mice were cocultured with OVA-challenged GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice, respectively, and analyzed by intracytoplasmic staining for their (<bold>A</bold>) TNFα, (<bold>B</bold>) IFNγ and (<bold>C</bold>) FoxP3 expression using flow cytometry. n.s., no significant difference.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Cx3cr1<sup>+</sup> i-OCLs express immunosuppressive factors and control the immune function of Cx3cr1<sup>neg</sup> i-OCLs in vitro</title><p>RNA-seq data also revealed that both i-OCLs subsets expressed inflammation-associated genes in line with their capacity to induce TNFα and IFNγ-producing CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). However, Cx3cr1<sup>+</sup> i-OCLs had significant higher expression of immunosuppressive genes (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) that could contribute to their lower inflammatory potential. Further RT-qPCR of the immunosuppressive genes <italic>CD274</italic> (PD-L1), <italic>Lgals9</italic> (Galectin-9) and <italic>Tnfrsf14</italic> (HEVM) confirmed these findings (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Interestingly, blocking the PD-L1/PD-1 axis with an anti-PD-1 antibody in co-cultures of Cx3cr1<sup>+</sup> i-OCLs and CD4<sup>+</sup> T cells increased the capacity of Cx3cr1<sup>+</sup> i-OCLs to induce T cell proliferation (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). These findings reveal that PD-L1 plays a central role in the immunosuppressive potential of Cx3cr1<sup>+</sup> i-OCLs. They also suggest that Cx3cr1<sup>+</sup> i-OCLs could have an immunosuppressive effect on Cx3cr1<sup>neg</sup> i-OCLs. Therefore, we set up an immunosuppressive assay where OVA-loaded Cx3cr1<sup>neg</sup> i-OCLs were co-cultured with CFSE-labelled CD4<sup>+</sup> T cells from OT-II mice. Different ratios of Cx3cr1<sup>+</sup> i-OCLs not challenged with OVA (unable to directly activate OT-II T cells) were added to the culture (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Cx3cr1<sup>neg</sup> i-OCLs alone (ratio 1:0) highly stimulated CD4<sup>+</sup> T cell proliferation, which was dramatically decreased by the addition of Cx3cr1<sup>+</sup> i-OCLs (ratio 1:2; <xref ref-type="fig" rid="fig6">Figure 6E</xref>). These data demonstrate that Cx3cr1<sup>+</sup> i-OCLs are able to control the inflammatory activity of Cx3cr1<sup>neg</sup> i-OCLs in vitro, suggesting the existence of a novel mechanism of interaction between OCLs in inflammatory conditions that remains to be addressed in vivo.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Cx3cr1<sup>neg</sup> and Cx3cr1<sup>+</sup> subsets differ in their T cell activation capacity.</title><p>(<bold>A</bold>) Heatmap visualization of the z-scored expression for selected genes involved in T cell stimulation and inhibition that are differentially expressed between GFP<sup>+</sup> (Cx3cr1<sup>+</sup>) and GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice (adjusted p&lt;0.05, FC ≥2). (<bold>B</bold>) RT-qPCR analysis of immunosuppressive molecules. Graphs show three independent experiments conducted in triplicates. (<bold>C</bold>) Representative FACS histograms and quantification of the proliferation of CSFE-labelled CD4<sup>+</sup> T cell from OT-II mice cocultured with OVA-loaded Cx3cr1<sup>+</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice and an isotype antibody (left panel) or an anti-PD-1 antibody (right panel). (<bold>D</bold>) Schematic representation of the experimental setup. Sorted GFP<sup>neg</sup> (Cx3cr1<sup>neg</sup>) i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice were loaded with OVA for 3 hr and incubated with CFSE<sup>+</sup> CD4<sup>+</sup> T cells in the presence of different rations of non-OVA loaded GFP<sup>+</sup>(Cx3cr1<sup>+</sup>) i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. (<bold>E</bold>) FACS analysis and quantification of CFSE<sup>+</sup> CD4<sup>+</sup> T cells of OT-II mice cocultured in the presence of different ratios (1:0; 1:1; 1:2) between OVA-loaded Cx3cr1<sup>neg</sup> i-OCLs and Cx3cr1<sup>+</sup> i-OCLs (non-loaded with OVA) for 5 days. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; n.s., no significant difference.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study provides further evidence of OCL heterogeneity. We previously demonstrated the existence of t-OCLs priming CD4<sup>+</sup> Treg cells and i-OCLs inducing TNFα<sup>+</sup>CD4<sup>+</sup> T cells that emerge under different conditions (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). Here, we show that i-OCLs encompass two distinct populations of <italic>bona fide</italic> OCLs that can be distinguished by their <italic>Cx3cr1</italic> expression. Although these 2 i-OCL subsets prime TNFα-producing CD4<sup>+</sup> T cells and resorb, they display different capacities for bone resorption and immunosuppression. Moreover, they do not activate Treg cells, and thus, they differ considerably from t-OCLs (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). We also show that Cx3cr1<sup>+</sup> i-OCLs control the inflammatory activity of Cx3cr1<sup>neg</sup> i-OCLs in vitro, suggesting that different OCL subsets could interact with each other to control their immune activity, an hypothesis that remains to be investigated in vivo (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Heterogeneity of osteoclasts and underlying molecular mechanisms.</title><p>In steady state, BM progenitors differentiate into tolerogenic OCLs (t-OCLs) that are able to present antigens and induce CD4<sup>+</sup> Treg cells. During inflammation, inflammatory MNs and DCs are recruited to the BM and differentiate into i-OCLs. Approx. 25% of these i-OCLs can be characterized by their expression of Cx3cr1 while the majority of i-OCLs does not express this marker. Cx3cr1<sup>neg</sup> i-OCLs show significantly higher bone resorption activity in vitro compared to Cx3cr1<sup>+</sup> i-OCLs. Both i-OCL subsets act as antigen-presenting cells but differ in their T cell activation capacity that is higher for the Cx3cr1<sup>neg</sup> i-OCL subset. Both i-OCL subsets are able to induce TNFα-producing CD4<sup>+</sup> T cells, however the Cx3cr1<sup>+</sup> OCL subset express high levels of co-inhibitory molecules such as PD-L1 that reduce their capacity to activate T cells. Moreover, Cx3cr1<sup>+</sup> i-OCLs have an immune suppressive effect on Cx3cr1 <sup>neg</sup> i-OCLs by reducing their T cell proliferation capacity in vitro.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-fig7-v1.tif"/></fig><p>Cx3cr1 is involved in the development and progression of chronic inflammatory diseases, such as colitis and arthritis (<xref ref-type="bibr" rid="bib26">Kotani et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Rossini et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Tarrant et al., 2012</xref>) while Cx3cr1 deficiency reduces the severity of these diseases (<xref ref-type="bibr" rid="bib37">Niess and Adler, 2010</xref>; <xref ref-type="bibr" rid="bib45">Rossini et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Tarrant et al., 2012</xref>). Our results extend the protective effect of Cx3cr1 deficiency to OVX-induced bone destruction. As in inflammatory bowel disease, this model is driven by TNFα and RANK-L-producing CD4<sup>+</sup> T cells leading to the development of Cx3cr1<sup>+</sup> OCLs (<xref ref-type="bibr" rid="bib9">Cenci et al., 2000</xref>; <xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Weitzmann and Pacifici, 2006</xref>). As a chemokine receptor, Cx3cr1 is required for the migration of monocytic cells and was suggested to participate in the maintenance of OCL progenitors particularly in inflammatory conditions (<xref ref-type="bibr" rid="bib10">Charles et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">Han et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Hasegawa et al., 2019</xref>). Its ligand (Fractalkine/Cx3cl1) increases in OVX mice and osteoporotic patients and correlates with disease severity (<xref ref-type="bibr" rid="bib11">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Wang et al., 2017</xref>). Fractalkine-producing mesenchymal cells attract OCL precursors and support their differentiation (<xref ref-type="bibr" rid="bib16">Goto et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Matsuura et al., 2017</xref>). In agreement with these data, we demonstrate that the reduced bone loss in OVX Cx3cr1-deficient mice is related to a decrease in BM i-OCL precursors (DCs and Ly6C<sup>hi</sup> MNs) and a reduced osteoclastogenesis. Although Cx3cr1-deficient mice were reported to have slightly reduced bone density (<xref ref-type="bibr" rid="bib19">Hoshino et al., 2013</xref>), we only observed moderate but significant differences in OVX mice, highlighting the importance of Cx3cr1 in pathological bone destruction. Compared to previous reports (<xref ref-type="bibr" rid="bib19">Hoshino et al., 2013</xref>), we gained advantage from working on purified mature i-OCLs from Cx3cr1-deficient mice and we did not observe any significant variations when comparing Cx3cr1<sup>+</sup> i-OCLs from Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> and WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. Overall, our results demonstrate that the Cx3cr1/Cx3cl1 axis is essential for the increased BM recruitment and differentiation of i-OCL progenitors observed in OVX mice but that the Cx3cr1 protein <italic>per se</italic> is not involved in the resorption and immune function of fully mature i-OCLs.</p><p>This raises the question of the role of Cx3cr1 in a subset of mature i-OCLs. As OCLs permanently fuse with new monocytic cells (<xref ref-type="bibr" rid="bib22">Jacome-Galarza et al., 2019</xref>), Cx3cr1 could be considered as a marker for some of these progenitor cells that remains expressed in the resulting OCLs. However, Cx3cr1<sup>+</sup> OCLs are induced by inflammatory cytokines such as IL-17 and TNFα and arise in conditions associated with inflammatory bone destruction (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Madel et al., 2019</xref>). Furthermore, Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs significantly differ in the expression of genes involved in Cx3cr1-interacting pathways. For instance, Cx3cr1<sup>+</sup> OCLs show lower expression of <italic>Nr1d1,</italic> a Cx3cr1 inhibitor (<xref ref-type="bibr" rid="bib49">Song et al., 2018</xref>) and higher levels of <italic>Tlr4</italic> that mediates the positive effects of LPS on Cx3cr1 (<xref ref-type="bibr" rid="bib39">Panek et al., 2015</xref>). Furthermore, we observed that Cx3cr1<sup>+</sup> OCLs arise from both Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> progenitors (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>), indicating that <italic>Cx3cr1</italic> expression by some mature OCLs is inducible and not solely inherited from their progenitors.</p><p>In line with our observations in OCLs, Cx3cr1 is also a marker for MN and DC diversity (<xref ref-type="bibr" rid="bib15">Ginhoux et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Varol et al., 2009</xref>; <xref ref-type="bibr" rid="bib59">Yona et al., 2013</xref>). Depending on their environment, BM progenitors can differentiate into immunogenic Cx3cr1<sup>low/neg</sup>MHC-II<sup>hi</sup> DCs or Cx3cr1<sup>+</sup>MHC-II<sup>low</sup> macrophages with high antigen-uptake and a PD-L1-associated immunosuppressive function (<xref ref-type="bibr" rid="bib61">Zhang et al., 2012</xref>). In the gut mucosa, Cx3cr1<sup>hi</sup> macrophages efficiently take up antigens but induce lower T cell proliferation compared to CD103<sup>+</sup>Cx3cr1<sup>neg</sup> DCs (<xref ref-type="bibr" rid="bib47">Schulz et al., 2009</xref>). The balance between immunosuppressive Cx3cr1<sup>hi</sup> and inflammatory Cx3cr1<sup>low</sup> phagocytes in the gut is essential in controlling inflammatory responses in colitis (<xref ref-type="bibr" rid="bib42">Regoli et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Yin et al., 2012</xref>). Accordingly, Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs exert different immune functions. Cx3cr1<sup>+</sup> cells were more efficient in antigen uptake but less potent in T cell activation than Cx3cr1<sup>neg</sup> i-OCLs. In addition, as Cx3cr1<sup>hi</sup> macrophages, Cx3cr1<sup>+</sup> i-OCLs decrease T cell proliferation, notably via immunosuppressive molecules such as PD-L1, Galectin-9 and HVEM. These factors are major immune checkpoints involved in autoimmune disorders and tumor-induced immune suppression associated with T cell dysfunction, exhaustion, and low activation (<xref ref-type="bibr" rid="bib6">Bjordahl et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Cai and Freeman, 2009</xref>; <xref ref-type="bibr" rid="bib14">Francisco et al., 2009</xref>; <xref ref-type="bibr" rid="bib50">Tai et al., 2018</xref>). Thus, their high expression in Cx3cr1<sup>+</sup> i-OCLs further strengthens the hypothesis that Cx3cr1<sup>+</sup> i-OCLs act as immunosuppressive cells emerging upon inflammatory signals to regulate inflammation, which was confirmed in vitro by a functional immunosuppressive assay (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>The contribution of OCLs to an immunosuppressive BM microenvironment has been recently explored in the context of multiple myeloma (MM). Bone destruction in MM is supported by malignant plasma cells that favor OCL differentiation, including from DCs, through high RANK-L, IL-17 and TNFα production (<xref ref-type="bibr" rid="bib34">Mansour et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Noonan et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Tucci et al., 2011</xref>). In these conditions, OCLs suppress T cell activation via PD-L1, Galectin-9 and HVEM (<xref ref-type="bibr" rid="bib2">An et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Mansour et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Tai et al., 2018</xref>). Although OCL heterogeneity was not investigated in MM, osteoclastogenic conditions are similar to those supporting the differentiation of Cx3cr1<sup>+</sup> i-OCLs (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). Thus, our results provide new insights into the immunosuppressive property of OCLs and suggest that Cx3cr1<sup>+</sup> i-OCLs are likely to be involved in pathological conditions such as MM.</p><p>Although Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs both induce TNFα-producing CD4<sup>+</sup> T cells and are resorbing cells, we showed that mature Cx3cr1<sup>neg</sup> i-OCLs are more efficient to induce CD4<sup>+</sup> T cell proliferation and have a higher resorption capacity in vitro than Cx3cr1<sup>+</sup> i-OCLs. This suggests that Cx3cr1<sup>neg</sup> i-OCLs play a major role in inflammatory bone destruction such as in osteoporosis and chronic inflammatory diseases. Interestingly, when comparing Cx3cr1<sup>+</sup> i-OCLs from Cx3cr1-deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> and WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice no differences were observed. Thus, the Cx3cr1 protein as such is not essential for the immunomodulatory and bone resorbing function of Cx3cr1<sup>+</sup> i-OCLs. However, it remains a membrane marker allowing to distinguish between 2 i-OCLs subsets (namely Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs) exerting different immunomodulatory roles. Apart from the lack of Cx3cr1 expression and their immunogenic effect, there is currently no specific marker for the identification of Cx3cr1<sup>neg</sup> i-OCLs. Thus, an in-depth characterization of these cells is necessary to fully address their specific role. Interestingly, Cx3cr1<sup>neg</sup> i-OCLs induce high proportions of TNFα and IFNγ-producing CD4<sup>+</sup> T cells in vitro. These cytokines are potent inducers of Cx3cr1 and PD-L1 (<xref ref-type="bibr" rid="bib6">Bjordahl et al., 2013</xref>; <xref ref-type="bibr" rid="bib36">McGrath and Najafian, 2012</xref>; <xref ref-type="bibr" rid="bib52">Tsukamoto et al., 2019</xref>) suggesting that TNFα-producing T cells induced by Cx3cr1<sup>neg</sup> i-OCLs may participate in the regulation of Cx3cr1<sup>+</sup> i-OCLs. This observation supports the existence of a regulatory loop between pro-inflammatory Cx3cr1<sup>neg</sup> i-OCLs and immunosuppressive Cx3cr1<sup>+</sup> i-OCLs that negatively regulate Th1 cell activation to control inflammation and that remains to be confirmed in vivo. Therefore, our findings suggest that the balance between the 2 i-OCL subsets would be an important aspect of the immune regulation during inflammatory bone loss.</p><p>In summary, we describe 2 OCL subsets that arise during inflammation and that are characterized by their <italic>Cx3cr1</italic> expression (<xref ref-type="fig" rid="fig7">Figure 7</xref>). While Cx3cr1<sup>neg</sup> i-OCLs mediate inflammatory bone destruction, Cx3cr1<sup>+</sup> i-OCLs are more prone to immunosuppression. This might contribute to the regulation of inflammatory processes but also to maintain an immunosuppressive BM microenvironment. Therefore, our in vitro data suggest the existence of a negative feedback mechanism by a gatekeeper subset of <italic>Cx3cr1</italic>-expressing i-OCLs during inflammation. This strongly emphasizes the heterogeneity of i-OCLs and provides new insights in their inflammatory function. Our study uncovered a hitherto neglected OCL diversity that contributes to a deeper understanding of the balance between inflammation and immunosuppression in the BM. Interestingly, OCL-related reduction of T cell activation can be restored using anti-PD-1 antibodies. Thus Cx3cr1<sup>+</sup> i-OCLs might represent a novel promising target to overcome the OCL-mediated immunosuppression and restore an anti-tumorigenic BM microenvironment. On the other hand, our results suggest that Cx3cr1<sup>neg</sup> i-OCLs are promising targets against inflammatory bone destruction. A deeper comprehension of OCL diversity is therefore indispensable to identify more specific markers and to evaluate the therapeutic interest of targeting specific OCL subsets.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td>Cx3cr1<sup>GFP/+</sup></td><td><xref ref-type="bibr" rid="bib23">Jung et al., 2000</xref></td><td/><td>CDTA, CNRS, Orléans, France</td></tr><tr><td>Sequenced-based reagent</td><td><italic>Calcr</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">CTTCCATGCTGATCTTCTGG</named-content> and<named-content content-type="sequence">CAGATCTCCATTGGGCACAA</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Acp5</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">TGCCTACCTGTGTGGACATGA</named-content> and<named-content content-type="sequence">CACATAGCCCACACCGTTCTC</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Mmp9</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">TGAGTCCGGCAGACAATCCT</named-content> and <named-content content-type="sequence">CGCCCTGGATCTCAGCAATA</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Ctsk</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">CAGCAGAGGTGTGTACTATG</named-content> and <named-content content-type="sequence">GCGTTGTTCTTATTCCGAGC</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Atp6V0a3</italic>/<italic>Tcirg1</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">CGCTGCGAGGAACTGGAG</named-content> and <named-content content-type="sequence">AGCGTCAGACCTGCCCG</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Tnfrsf11a</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">CTTGGACACCTGGAATGAAGAAG</named-content> and <named-content content-type="sequence">AGGGCCTTGCCTGCATC</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Nfatc1</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">TGAGGCTGGTCTTCCGAGTT</named-content> and <named-content content-type="sequence">CGCTGGGAACACTCGATAGG</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Dcstamp</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">GGGCACCAGTATTTTCCTGA</named-content> and <named-content content-type="sequence">CAGAACGGCCAGAAGAATGA</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Oscar</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">GTAACGGATCAGCTCCCCAG</named-content> and <named-content content-type="sequence">CGCGGTACAGTGCAAAACTC</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>CD274</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">CAAGCGAATCACGCTGAAAG</named-content> and <named-content content-type="sequence">GGGTTGGTGGTCACTGTTTGT</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Lgals9</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">TCAAGGTGATGGTGAACAAGAAA</named-content> and <named-content content-type="sequence">GATGGTGTCCACGAGGTGGTA</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>Lightr/Tnfrsf14</italic></td><td/><td>PCR primers</td><td> <named-content content-type="sequence">TGTCCATTCTTTTGCCACTTG</named-content> and <named-content content-type="sequence">CCTGATGGTGTTCTCCTGTTGTT</named-content></td></tr><tr><td>Sequenced-based reagent</td><td><italic>36B4</italic></td><td/><td>PCR primers</td><td><named-content content-type="sequence">TCCAGGCTTTGGGCATCA</named-content> and <named-content content-type="sequence">CTTTATCAGCTGCACATCACTCAGA</named-content></td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse CD80</td><td>BD Biosciences</td><td>clone 16-10A1</td><td>APC-conjugated <break/>(1:100)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse CD86</td><td>BD Biosciences</td><td>clone GL1</td><td>PE-conjugated <break/>(1:100)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse I-A[b]</td><td>BD Biosciences</td><td>clone AF6-120.1</td><td>Biotin-conjugated <break/>(1:200)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse/human CD11b</td><td>BD Biosciences</td><td>clone M1/70</td><td>PE-conjugated <break/>(1:500)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse CD4</td><td>BD Biosciences</td><td>clone RM4-5</td><td>PECy7-conjugated <break/>(1:1000)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse CD68</td><td>ThermoFisher Scientific</td><td>clone FA-11</td><td>PECy7-conjugated <break/>(1:200)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse CD11c</td><td>ThermoFisher Scientific</td><td>clone N418</td><td>PECy7-conjugated <break/>(1:200)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse Ly6C</td><td>ThermoFisher Scientific</td><td>clone HK1.4</td><td>PerCP-conjugated <break/>(1:1000)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse CD169</td><td>ThermoFisher Scientific</td><td>clone SER-4</td><td>APC-conjugated <break/>(1:100)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse IFNγ</td><td>ThermoFisher Scientific</td><td>clone XMG1.2</td><td>APC-conjugated <break/>(1:400)</td></tr><tr><td>Antibody</td><td>Monoclonal anti-mouse TNFα</td><td>ThermoFisher Scientific</td><td>clone MP6-XT22</td><td>BV421-conjugated <break/>(1:400)</td></tr><tr><td>Chemical compound, drug</td><td>streptavidin</td><td>ThermoFisher Scientific</td><td/><td>PercP-conjugated <break/>(1:200)</td></tr><tr><td>Chemical compound, drug</td><td>ovalbumin</td><td>ThermoFisher Scientific</td><td/><td>Alexa Fluor 647-conjugated</td></tr><tr><td>Commercial assay or kit</td><td>Acid Phosphatase Leucocyte (TRAcP) kit</td><td>Sigma-Aldrich</td><td>387A</td><td/></tr><tr><td>Commercial assay or kit</td><td>ELF 97 Endogenous Phosphatase Detection Kit</td><td>Molecular probes</td><td>E-6601</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice and ovariectomy-induced osteoporosis</title><p>OT-II mice were purchased from Charles River Laboratory and C57BL/6 <italic>Cx3cr1</italic><sup>GFP/+</sup> mice were kindly provided by F. Laurent (INRA, Nouzilly, France). Animals were maintained under a 12 hr light/12 hr dark cycle with free access to water and standard mouse diet. For ovariectomy, female mice were randomly divided into 2 groups, which were then sham-operated (SHAM) or ovariectomized (OVX). Ovariectomy and sham surgery were performed on 6 weeks old <italic>Cx3cr1</italic><sup>GFP/+</sup> and <italic>Cx3cr1</italic><sup>GFP/GFP</sup> female mice after anesthesia with isoflurane. The animals were intensively monitored for 72 hr after the procedure. Animals were weighed at the beginning of the study and twice a week thereafter. Six weeks after ovariectomy, mice were sacrificed. Uteri were weighed to control the quality of ovariectomy (not shown). Bones were used either for bone marrow cell isolation and further flow cytometry analysis or for subsequent µCT and histological analysis. Approval for animal experiments was obtained from the Institutional Ethics Committee on Laboratory Animals (CIEPAL-Azur, Nice Sophia-Antipolis, France) and experiments were conducted in compliance with ethical regulations for animal testing and research.</p></sec><sec id="s4-2"><title>Bone analyses</title><p>Femora were fixed in 4% paraformaldehyde (PFA) overnight. Subsequently, microcomputed tomography (µCT) was performed using the Skyscan 1176 µCT system (Bruker µCT, Belgium) at the preclinical platform ECELLFRANCE (IRMB, Montpellier, France). Scans were performed using isotropic voxels size of 18 µm, voltage of 50 kV, current of 500 mA, 0.5 mm aluminum filter, 180 degrees with a 0.7-degree rotation step and 210 ms exposure time. Data 3D reconstructions were generated for visual representation using NRecon software (Bruker µCT, Belgium).</p><p>For histological analysis, fixed femora were decalcified in 10% EDTA for 10 days, embedded in paraffin and tartrate-resistant acid phosphatase (TRAcP) staining was performed on 7 µm sections following manufacturer’s recommendations (Sigma).</p></sec><sec id="s4-3"><title>Primary osteoclast culture</title><p>As OCLs cannot be isolated directly ex vivo in sufficient number for subsequent functional analysis, inflammatory OCLs (i-OCLs) were differentiated in vitro from BM-derived CD11c<sup>+</sup> DCs or from blood CD11b<sup>+</sup> Ly6C<sup>hi</sup> MNs of 6 week old WT <italic>Cx3cr1</italic><sup>GFP/+</sup> and deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice as previously described (<xref ref-type="bibr" rid="bib20">Ibáñez et al., 2016</xref>). Briefly, bone marrow was flushed out of the long bones and after red blood cell lysis, BM cells were cultured in 24-well plates at 0.5 × 10<sup>6</sup> cells/well in RPMI medium (ThermoFisher Scientific) supplemented with 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin, 50 µM β-mercaptoethanol (both from ThermoFisher Scientific), 10 ng/ml IL-4 and 10 ng/ml GM-CSF (both from PeproTech). CD11c<sup>+</sup> DCs were sorted using anti-CD11c antibody (1:200; HL3; BD Biosciences) and anti-biotin microbeads (Miltenyi Biotec). Alternatively, when indicated, i-OCLs were obtained from blood SSC<sup>lo</sup> CD11b<sup>+</sup> Ly6C<sup>hi</sup> MNs of <italic>Cx3cr1</italic><sup>GFP/+</sup> OVX mice sorted on a FACS-Aria II (BD Biosciences) using anti-CD11b and Ly6C antibodies. For i-OCLs culture, 2 × 10<sup>4</sup> CD11c<sup>+</sup> DCs or CD11b<sup>+</sup> Ly6C<sup>hi</sup> MNs were seeded/well on 24-well plates in MEM-alpha (ThermoFisher Scientific) supplemented with 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin, 50 µM β-mercaptoethanol, 25 ng/ml M-CSF and 30 ng/ml RANK-L (both R and D). Cells were cultured at 37°C and 5% CO<sub>2</sub>. Medium was changed every 3–4 days. Fully differentiated i-OCLs were stained with TRAcP (Sigma-Aldrich) according to manufacturer’s instructions or collected from the culture plates using Accutase (Sigma-Aldrich) and used for subsequent FACS analysis or FACS sorting based on their nuclei number using H33342 (Sigma-Aldrich) as described previously (<xref ref-type="bibr" rid="bib30">Madel et al., 2018</xref>). When indicated, macrophages were differentiated in vitro from total BM cells (0.5 × 10<sup>6</sup> BM cells/well in 24-well plates) in MEM-alpha supplemented with 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin, 50 µM β-mercaptoethanol and 25 ng/ml M-CSF for a total of 6 days.</p></sec><sec id="s4-4"><title>FACS and cell sorting on osteoclasts</title><p>Mature in vitro differentiated i-OCLs were analyzed and sorted based on their multinucleation and GFP expression as described previously (<xref ref-type="bibr" rid="bib30">Madel et al., 2018</xref>) using flow cytometry analysis. Briefly, cells were incubated with 5 µg/ml H33342 (Sigma-Aldrich) in PBS 1X supplemented with 1% FBS and 2 mM EDTA (PSE) for 30 min at 37°C. For cell sorting, cells were filtered through a 100 µm nylon mesh and sorted on a FACS Aria IIu (BD Bioscience) using a 100 µm nozzle at a flow rate of 2000 events/s. Sorted cells were collected in FBS. Hoechst-stained i-OCLs from <italic>Cx3cr1</italic><sup>GFP</sup> mutant mice were labeled with antibodies specific for murine anti-CD80, CD86 and IAb (MHC-II, biotinylated) antibodies with a PercP-conjugated streptavidin in PSE for 15 min on ice. For antigen-uptake, mature OCLs were collected and incubated in the presence of 25 µg/ml ovalbumin (ThermoFisher Scientific) for 2.5 hr at 37°C before adding 5 µg/ml H33342 staining for another 30 min and subsequent FACS acquisition. Gating strategies for Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs are shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>. For FACS analysis of TRAcP expression, OCLs were stained using the ELF97 substrate according to the manufacturer's protocol (endogenous phosphatase detection kit; Molecular Probes).</p><p>For ex vivo FACS analysis of OCL progenitors, after red blood cell lysis (Sigma-Aldrich) BM cells were labelled with anti-CD11c, CD11b and Ly6C antibodies. For FACS analysis of macrophages, BM-derived macrophages were labeled with anti-CD68 and CD169 antibodies.</p><p>For intracellular cytokine analysis, CD4<sup>+</sup> T cells were stimulated with PMA, ionomycin and Brefeldin A, labelled with an anti-CD4 antibody and fixed with 4% formaldehyde overnight as described (<xref ref-type="bibr" rid="bib12">Ciucci et al., 2015</xref>). Cells were stained with anti-IFNγ and TNFα antibodies in Saponin 1X. Data were acquired using a FACS Canto-II (BD Biosciences).</p></sec><sec id="s4-5"><title>Resorption assay</title><p>Mature in vitro differentiated i-OCLs were sorted based on their multinucleation and GFP (Cx3cr1) expression as described above (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib30">Madel et al., 2018</xref>). A total of 10<sup>3</sup> Cx3cr1<sup>+</sup> or Cx3cr1<sup>neg</sup> i-OCLs was seeded/well on a 96-well osteoassay plate (Corning) in MEM-alpha containing 10% FBS (Hyclone, GE Healthcare) and 30 ng/ml RANK-L (R and D). After 48 hr, matrix dissolution activity was evaluated by removing the cells using distilled sterile water and staining with 2% Alizarin Red (Sigma-Aldrich) for 1 min. Imaging was performed using an Axio Observer D1 microscope (Zeiss) and images were taken using AxioVision Rel. 4.8 software (Zeiss). Resorbed areas were quantified using Fiji/ImageJ software (<xref ref-type="bibr" rid="bib46">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-6"><title>T cell proliferation and immune suppression assay</title><p>Mature in vitro differentiated Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs were sorted based on their multinucleation and GFP expression as mentioned above (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and seeded on 96-well plates with 10<sup>3</sup> cells/well in the presence of 600 nM ovalbumin (OVA) peptide (ThermoFisher Scientific). Spleens of 8 weeks old OT-II mice were used to isolate CD4<sup>+</sup> T cells that express transgenic OVA-specific αβ-TCRs by using the Dynabeads Untouched Mouse CD4 Cell Isolation Kit (ThermoFisher Scientific) according to manufacturer’s specifications. To analyze T cell proliferation, CD4<sup>+</sup> T cells were labelled with 250 µM CFSE for 10 min at 37°C. OVA-loaded i-OCLs and CD4<sup>+</sup> T cells were seeded in a ratio 1:20 in IMDM medium supplemented with 5% FCS (Hyclone, GE Healthcare), 1% penicillin-streptomycin (Gibco) and 50 µM β-mercaptoethanol (Gibco). T cell proliferation was assessed by FACS after 3–5 days.</p><p>Implication of the PD-1/PD-L1 axis was evaluated by adding 5 µg/ml isotype control or anti-PD-1 (clone Rpm 14–1; kindly provided by V. Vouret (IRCAN, Nice, France)) antibodies at the beginning to the coculture. To validate the immune suppressive effect of Cx3cr1<sup>+</sup> i-OCLs, sorted Cx3cr1<sup>neg</sup> i-OCLs were stimulated with 600 nM OVA for 3 hr at 37°C, washed 3 times with IMDM medium and cultured together with CFSE-labelled CD4<sup>+</sup> T cells from transgenic OT-II mice on 96-well plates as described above. Cx3cr1<sup>+</sup> i-OCLs were sorted and added to the coculture without ovalbumin challenge in different ratios between Cx3cr1<sup>neg</sup> vs Cx3cr1<sup>+</sup> i-OCLs (1:1; 1:2; 2:1). T cell proliferation was assessed using FACS after 3–5 days of coculture.</p></sec><sec id="s4-7"><title>RNA sequencing on sorted osteoclasts</title><p>Total RNA (100 ng) from 4 biological replicates (from 4 different mice) in each group was extracted from in vitro differentiated i-OCLs (after sorting according to their multinucleation and GFP expression as described above and shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) with the RNeasy kit (Qiagen) and processed for directional library preparation using the Truseq stranded total RNA library kit (Illumina). Libraries were pooled and sequenced paired-ended for 2 × 75 cycles on a Nextseq500 sequencer (Illumina) to generate 30–40 million fragments per sample. After quality controls, data analysis was performed with 2 different approaches. For the first one, reads were ‘quasi’ mapped on the reference mouse transcriptome (Gencode vM15) and quantified using the SALMON software with the mapping mode and standard settings (<xref ref-type="bibr" rid="bib40">Patro et al., 2017</xref>). Estimates of transcripts counts and their confidence intervals were computed using 1000 bootstraps to assess technical variance. Gene expression levels were computed by aggregating the transcript counts for each gene. Gene expression in biological replicates (n = 4) was then compared using a linear model as implemented in Sleuth (<xref ref-type="bibr" rid="bib41">Pimentel et al., 2017</xref>) and a false discovery rate of 0.01. Lists of differentially expressed genes were annotated using Innate-DB and EnrichR web portals. For the second approach, raw RNAseq fastq reads were trimmed with Trimmomatic and aligned to the reference mouse transcriptome (Gencode mm10) using STAR (v. 2.6.1 c) (<xref ref-type="bibr" rid="bib13">Dobin et al., 2013</xref>) on the National Institutes of Health high-performance computing Biowulf cluster. Gene-assignment and estimates counts of RNA reads were performed with HTseq (<xref ref-type="bibr" rid="bib3">Anders et al., 2015</xref>). Further analyses were performed with R software and gene expression in biological replicates (n = 4) was compared between the different conditions to identify differentially expressed genes using DESeq2 (<xref ref-type="bibr" rid="bib29">Love et al., 2014</xref>) with the Wald test (FDR &lt; 0.01). Batch removal was performed using limma (<xref ref-type="bibr" rid="bib43">Ritchie et al., 2015</xref>). Gene ontology (GO) pathway analyzes were performed using Goseq (<xref ref-type="bibr" rid="bib60">Young et al., 2010</xref>). Both approaches gave equivalent results (not shown).</p></sec><sec id="s4-8"><title>Gene expression analyses</title><p>Total RNA of sorted in vitro differentiated Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs was extracted using TRIzol reagent with subsequent isopropanol precipitation following manufacturer’s instructions. RT-qPCR was performed after reverse transcription (Superscript II, Life Technologies) as described previously (<xref ref-type="bibr" rid="bib33">Mansour et al., 2012</xref>) using SYBR Green and the primers indicated in the Key ressources table. Samples of 3 biological replicates were run in triplicates and results were normalized to the reference gene <italic>36B4</italic> using the 2<sup>−ΔCt</sup> method as described (<xref ref-type="bibr" rid="bib32">Mansour et al., 2011</xref>).</p></sec><sec id="s4-9"><title>Statistical analyses</title><p>All data were analyzed using Graph Pad Prism 7.0 software using an appropriate two tailed student’s <italic>t</italic>-test with Bonferroni adjustment when comparing two groups. When more than two groups were compared two-way analysis of variance (ANOVA) was used. Statistical significance was considered at p&lt;0.05. Experimental values are presented as mean ± standard deviation (SD) of at least three biological replicas. Error bars for gene expression analysis of humans and mice using RT-qPCR show the mean value with 95% confidence interval. All experiments were repeated with a minimum of three biological replicates and at least two technical replicates.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We acknowledge M Topi (LP2M, Nice, France) for her technical assistance, the Genomic Facility of the UFR Simone Veil, (Université Versailles-Saint-Quentin, France) for the RNA sequencing, the IRCAN animal core facility (Nice, France) and the preclinical platform of ECELLFRANCE for µCT analysis (IRMB, Montpellier, France). This work utilized the computational resources of the NIH-HPC-Biowulf cluster (<ext-link ext-link-type="uri" xlink:href="http://hpc.nih.gov">http://hpc.nih.gov</ext-link>).</p><p>The work was supported by the Agence Nationale de la Recherche (ANR-16-CE14-0030), the French government, managed by the ANR as part of the Investissement d’Avenir UCA<sup>JEDI</sup> project (ANR-15-IDEX-01), the Fondation Arthritis, Société Française de Biologie des Tissus Minéralisés, European Calcified Tissue Society and American Society of Bone and Mineral Research. M-B M is supported by the Fondation pour la Recherche Médicale (FRM, ECO20160736019) and TC is supported by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institutes of Health.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Visualization, Writing - review and editing, contributed to the discussion of results and provided helpful advices throughout the study</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Data curation, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Supervision, Writing - review and editing, Contributed to the discussion of results and provided helpful advices throughout the study</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Validation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The protocol for animal experiments was approved by the Institutional Ethics Committee on Laboratory Animals (CIEPAL-Azur, France) (#2016121216457153 (V3). Experiments were conducted in compliance with ethical regulations for animal testing and research.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Raw counts-HTSeq.</title><p>Raw counts (HTseq) per gene and per sample from the RNAseq analysis of Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice and Cx3cr1<sup>+</sup> i-OCLs from deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54493-data1-v1.xlsx"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Counts_Deseq NormaBatch Corrected.</title><p>Counts per gene and per sample after normalization and batch correction from the RNAseq analysis of Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice and Cx3cr1<sup>+</sup> i-OCLs from deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54493-data2-v1.xlsx"/></supplementary-material><supplementary-material id="sdata3"><label>Source data 3.</label><caption><title>Cx3cr1<sup>+</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice versus Cx3cr1<sup>+</sup> i-OCLs from deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice _Deseq.</title><p>Statistics (Deseq) for the comparison of expressed genes in Cx3cr1<sup>+</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice versus Cx3cr1<sup>+</sup> i-OCLs from deficient <italic>Cx3cr1</italic><sup>GFP/GFP</sup> mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54493-data3-v1.xlsx"/></supplementary-material><supplementary-material id="sdata4"><label>Source data 4.</label><caption><title>Cx3cr1<sup>+</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice versus Cx3cr1<sup>neg</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice mice _Deseq.</title><p>Statistics (Deseq) for the comparison of expressed genes in Cx3cr1<sup>+</sup> versus Cx3cr1<sup>neg</sup> i-OCLs from WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54493-data4-v1.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-54493-transrepform-v1.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All the RNA sequencing data are included in the submitted manuscript as data source files. RNA-Sequencing data have been deposited in ENA (European Nucleotide Archive) under accession number PRJEB36092.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Madel</surname><given-names>MB</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Heterogeneity of inflammatory osteoclasts based on CX3CR1 expression</data-title><source>European Nucleotide Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/data/view/PRJEB36092">PRJEB36092</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammari</surname> <given-names>M</given-names></name><name><surname>Presumey</surname> <given-names>J</given-names></name><name><surname>Ponsolles</surname> <given-names>C</given-names></name><name><surname>Roussignol</surname> <given-names>G</given-names></name><name><surname>Roubert</surname> <given-names>C</given-names></name><name><surname>Escriou</surname> <given-names>V</given-names></name><name><surname>Toupet</surname> <given-names>K</given-names></name><name><surname>Mausset-Bonnefont</surname> <given-names>AL</given-names></name><name><surname>Cren</surname> <given-names>M</given-names></name><name><surname>Robin</surname> <given-names>M</given-names></name><name><surname>Georgel</surname> <given-names>P</given-names></name><name><surname>Nehmar</surname> <given-names>R</given-names></name><name><surname>Taams</surname> <given-names>L</given-names></name><name><surname>Grün</surname> <given-names>J</given-names></name><name><surname>Grützkau</surname> <given-names>A</given-names></name><name><surname>Häupl</surname> <given-names>T</given-names></name><name><surname>Pers</surname> <given-names>YM</given-names></name><name><surname>Jorgensen</surname> <given-names>C</given-names></name><name><surname>Duroux-Richard</surname> <given-names>I</given-names></name><name><surname>Courties</surname> <given-names>G</given-names></name><name><surname>Apparailly</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Delivery of miR-146a to Ly6C high monocytes inhibits pathogenic bone erosion in inflammatory arthritis</article-title><source>Theranostics</source><volume>8</volume><fpage>5972</fpage><lpage>5985</lpage><pub-id pub-id-type="doi">10.7150/thno.29313</pub-id><pub-id pub-id-type="pmid">30613275</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname> <given-names>G</given-names></name><name><surname>Acharya</surname> <given-names>C</given-names></name><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Wen</surname> <given-names>K</given-names></name><name><surname>Zhong</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Munshi</surname> <given-names>NC</given-names></name><name><surname>Qiu</surname> <given-names>L</given-names></name><name><surname>Tai</surname> <given-names>YT</given-names></name><name><surname>Anderson</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication</article-title><source>Blood</source><volume>128</volume><fpage>1590</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-03-707547</pub-id><pub-id pub-id-type="pmid">27418644</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname> <given-names>S</given-names></name><name><surname>Pyl</surname> <given-names>PT</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname> <given-names>F</given-names></name><name><surname>Miyamoto</surname> <given-names>T</given-names></name><name><surname>Ohneda</surname> <given-names>O</given-names></name><name><surname>Inada</surname> <given-names>T</given-names></name><name><surname>Sudo</surname> <given-names>T</given-names></name><name><surname>Brasel</surname> <given-names>K</given-names></name><name><surname>Miyata</surname> <given-names>T</given-names></name><name><surname>Anderson</surname> <given-names>DM</given-names></name><name><surname>Suda</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors</article-title><source>The Journal of Experimental Medicine</source><volume>190</volume><fpage>1741</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1084/jem.190.12.1741</pub-id><pub-id pub-id-type="pmid">10601350</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnden</surname> <given-names>MJ</given-names></name><name><surname>Allison</surname> <given-names>J</given-names></name><name><surname>Heath</surname> <given-names>WR</given-names></name><name><surname>Carbone</surname> <given-names>FR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements</article-title><source>Immunology and Cell Biology</source><volume>76</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1711.1998.00709.x</pub-id><pub-id pub-id-type="pmid">9553774</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjordahl</surname> <given-names>RL</given-names></name><name><surname>Steidl</surname> <given-names>C</given-names></name><name><surname>Gascoyne</surname> <given-names>RD</given-names></name><name><surname>Ware</surname> <given-names>CF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lymphotoxin network pathways shape the tumor microenvironment</article-title><source>Current Opinion in Immunology</source><volume>25</volume><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2013.01.001</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchwald</surname> <given-names>ZS</given-names></name><name><surname>Kiesel</surname> <given-names>JR</given-names></name><name><surname>DiPaolo</surname> <given-names>R</given-names></name><name><surname>Pagadala</surname> <given-names>MS</given-names></name><name><surname>Aurora</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Osteoclast Activated FoxP3+ CD8+ T-Cells Suppress Bone Resorption in vitro</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e38199</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0038199</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname> <given-names>G</given-names></name><name><surname>Freeman</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation</article-title><source>Immunological Reviews</source><volume>229</volume><fpage>244</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00783.x</pub-id><pub-id pub-id-type="pmid">19426226</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cenci</surname> <given-names>S</given-names></name><name><surname>Weitzmann</surname> <given-names>MN</given-names></name><name><surname>Roggia</surname> <given-names>C</given-names></name><name><surname>Namba</surname> <given-names>N</given-names></name><name><surname>Novack</surname> <given-names>D</given-names></name><name><surname>Woodring</surname> <given-names>J</given-names></name><name><surname>Pacifici</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha</article-title><source>Journal of Clinical Investigation</source><volume>106</volume><fpage>1229</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1172/JCI11066</pub-id><pub-id pub-id-type="pmid">11086024</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname> <given-names>JF</given-names></name><name><surname>Hsu</surname> <given-names>LY</given-names></name><name><surname>Niemi</surname> <given-names>EC</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Aliprantis</surname> <given-names>AO</given-names></name><name><surname>Nakamura</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>4592</fpage><lpage>4605</lpage><pub-id pub-id-type="doi">10.1172/JCI60920</pub-id><pub-id pub-id-type="pmid">23114597</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>YD</given-names></name><name><surname>Huang</surname> <given-names>CY</given-names></name><name><surname>Liu</surname> <given-names>HY</given-names></name><name><surname>Yao</surname> <given-names>WF</given-names></name><name><surname>Wu</surname> <given-names>WG</given-names></name><name><surname>Lu</surname> <given-names>YL</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Serum CX3CL1/fractalkine concentrations are positively associated with disease severity in postmenopausal osteoporotic patients</article-title><source>British Journal of Biomedical Science</source><volume>73</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1080/09674845.2016.1209897</pub-id><pub-id pub-id-type="pmid">27476376</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciucci</surname> <given-names>T</given-names></name><name><surname>Ibáñez</surname> <given-names>L</given-names></name><name><surname>Boucoiran</surname> <given-names>A</given-names></name><name><surname>Birgy-Barelli</surname> <given-names>E</given-names></name><name><surname>Pène</surname> <given-names>J</given-names></name><name><surname>Abou-Ezzi</surname> <given-names>G</given-names></name><name><surname>Arab</surname> <given-names>N</given-names></name><name><surname>Rouleau</surname> <given-names>M</given-names></name><name><surname>Hébuterne</surname> <given-names>X</given-names></name><name><surname>Yssel</surname> <given-names>H</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name><name><surname>Wakkach</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bone marrow Th17 tnfα cells induce osteoclast differentiation, and link bone destruction to IBD</article-title><source>Gut</source><volume>64</volume><fpage>1072</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2014-306947</pub-id><pub-id pub-id-type="pmid">25298539</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francisco</surname> <given-names>LM</given-names></name><name><surname>Salinas</surname> <given-names>VH</given-names></name><name><surname>Brown</surname> <given-names>KE</given-names></name><name><surname>Vanguri</surname> <given-names>VK</given-names></name><name><surname>Freeman</surname> <given-names>GJ</given-names></name><name><surname>Kuchroo</surname> <given-names>VK</given-names></name><name><surname>Sharpe</surname> <given-names>AH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>PD-L1 regulates the development, maintenance, and function of induced regulatory T cells</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>3015</fpage><lpage>3029</lpage><pub-id pub-id-type="doi">10.1084/jem.20090847</pub-id><pub-id pub-id-type="pmid">20008522</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginhoux</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>K</given-names></name><name><surname>Helft</surname> <given-names>J</given-names></name><name><surname>Bogunovic</surname> <given-names>M</given-names></name><name><surname>Greter</surname> <given-names>M</given-names></name><name><surname>Hashimoto</surname> <given-names>D</given-names></name><name><surname>Price</surname> <given-names>J</given-names></name><name><surname>Yin</surname> <given-names>N</given-names></name><name><surname>Bromberg</surname> <given-names>J</given-names></name><name><surname>Lira</surname> <given-names>SA</given-names></name><name><surname>Stanley</surname> <given-names>ER</given-names></name><name><surname>Nussenzweig</surname> <given-names>M</given-names></name><name><surname>Merad</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The origin and development of nonlymphoid tissue CD103<sup>+</sup> DCs</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>3115</fpage><lpage>3130</lpage><pub-id pub-id-type="doi">10.1084/jem.20091756</pub-id><pub-id pub-id-type="pmid">20008528</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname> <given-names>Y</given-names></name><name><surname>Aoyama</surname> <given-names>M</given-names></name><name><surname>Sekiya</surname> <given-names>T</given-names></name><name><surname>Kakita</surname> <given-names>H</given-names></name><name><surname>Waguri-Nagaya</surname> <given-names>Y</given-names></name><name><surname>Miyazawa</surname> <given-names>K</given-names></name><name><surname>Asai</surname> <given-names>K</given-names></name><name><surname>Goto</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CXCR4 <sup>+</sup> CD45 <sup>−</sup>cells are niche forming for osteoclastogenesis via the SDF-1, CXCL7, and CX3CL1 signaling pathways in bone marrow: cxcr4 <sup>+</sup> CD45 <sup>−</sup>cells in osteoclastogenesis</article-title><source>Stem Cells</source><volume>34</volume><fpage>2733</fpage><lpage>2743</lpage><pub-id pub-id-type="doi">10.1002/stem.2440</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>KH</given-names></name><name><surname>Ryu</surname> <given-names>JW</given-names></name><name><surname>Lim</surname> <given-names>KE</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Hwang</surname> <given-names>CS</given-names></name><name><surname>Choi</surname> <given-names>JY</given-names></name><name><surname>Han</surname> <given-names>KO</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Vascular expression of the chemokine CX3CL1 promotes osteoclast recruitment and exacerbates bone resorption in an irradiated murine model</article-title><source>Bone</source><volume>61</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2013.12.032</pub-id><pub-id pub-id-type="pmid">24401612</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname> <given-names>T</given-names></name><name><surname>Kikuta</surname> <given-names>J</given-names></name><name><surname>Sudo</surname> <given-names>T</given-names></name><name><surname>Matsuura</surname> <given-names>Y</given-names></name><name><surname>Matsui</surname> <given-names>T</given-names></name><name><surname>Simmons</surname> <given-names>S</given-names></name><name><surname>Ebina</surname> <given-names>K</given-names></name><name><surname>Hirao</surname> <given-names>M</given-names></name><name><surname>Okuzaki</surname> <given-names>D</given-names></name><name><surname>Yoshida</surname> <given-names>Y</given-names></name><name><surname>Hirao</surname> <given-names>A</given-names></name><name><surname>Kalinichenko</surname> <given-names>VV</given-names></name><name><surname>Yamaoka</surname> <given-names>K</given-names></name><name><surname>Takeuchi</surname> <given-names>T</given-names></name><name><surname>Ishii</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1</article-title><source>Nature Immunology</source><volume>20</volume><fpage>1631</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0526-7</pub-id><pub-id pub-id-type="pmid">31740799</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname> <given-names>A</given-names></name><name><surname>Ueha</surname> <given-names>S</given-names></name><name><surname>Hanada</surname> <given-names>S</given-names></name><name><surname>Imai</surname> <given-names>T</given-names></name><name><surname>Ito</surname> <given-names>M</given-names></name><name><surname>Yamamoto</surname> <given-names>K</given-names></name><name><surname>Matsushima</surname> <given-names>K</given-names></name><name><surname>Yamaguchi</surname> <given-names>A</given-names></name><name><surname>Iimura</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts</article-title><source>Journal of Cell Science</source><volume>126</volume><fpage>1032</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1242/jcs.113910</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibáñez</surname> <given-names>L</given-names></name><name><surname>Abou-Ezzi</surname> <given-names>G</given-names></name><name><surname>Ciucci</surname> <given-names>T</given-names></name><name><surname>Amiot</surname> <given-names>V</given-names></name><name><surname>Belaïd</surname> <given-names>N</given-names></name><name><surname>Obino</surname> <given-names>D</given-names></name><name><surname>Mansour</surname> <given-names>A</given-names></name><name><surname>Rouleau</surname> <given-names>M</given-names></name><name><surname>Wakkach</surname> <given-names>A</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammatory osteoclasts prime TNFα-Producing CD4+ T Cells and Express CX3 CR1</article-title><source>Journal of Bone and Mineral Research</source><volume>31</volume><fpage>1899</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2868</pub-id><pub-id pub-id-type="pmid">27161765</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacome-Galarza</surname> <given-names>CE</given-names></name><name><surname>Lee</surname> <given-names>S-K</given-names></name><name><surname>Lorenzo</surname> <given-names>JA</given-names></name><name><surname>Aguila</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery</article-title><source>Journal of Bone and Mineral Research</source><volume>28</volume><fpage>1203</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1822</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacome-Galarza</surname> <given-names>CE</given-names></name><name><surname>Percin</surname> <given-names>GI</given-names></name><name><surname>Muller</surname> <given-names>JT</given-names></name><name><surname>Mass</surname> <given-names>E</given-names></name><name><surname>Lazarov</surname> <given-names>T</given-names></name><name><surname>Eitler</surname> <given-names>J</given-names></name><name><surname>Rauner</surname> <given-names>M</given-names></name><name><surname>Yadav</surname> <given-names>VK</given-names></name><name><surname>Crozet</surname> <given-names>L</given-names></name><name><surname>Bohm</surname> <given-names>M</given-names></name><name><surname>Loyher</surname> <given-names>P-L</given-names></name><name><surname>Karsenty</surname> <given-names>G</given-names></name><name><surname>Waskow</surname> <given-names>C</given-names></name><name><surname>Geissmann</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Developmental origin, functional maintenance and genetic rescue of osteoclasts</article-title><source>Nature</source><volume>568</volume><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1105-7</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname> <given-names>S</given-names></name><name><surname>Aliberti</surname> <given-names>J</given-names></name><name><surname>Graemmel</surname> <given-names>P</given-names></name><name><surname>Sunshine</surname> <given-names>MJ</given-names></name><name><surname>Kreutzberg</surname> <given-names>GW</given-names></name><name><surname>Sher</surname> <given-names>A</given-names></name><name><surname>Littman</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>4106</fpage><lpage>4114</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.11.4106-4114.2000</pub-id><pub-id pub-id-type="pmid">10805752</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiesel</surname> <given-names>JR</given-names></name><name><surname>Buchwald</surname> <given-names>ZS</given-names></name><name><surname>Aurora</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cross-presentation by osteoclasts induces FoxP3 in CD8<sup>+</sup> T cells</article-title><source>Journal of Immunology</source><volume>182</volume><fpage>5477</fpage><lpage>5487</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803897</pub-id><pub-id pub-id-type="pmid">19380796</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname> <given-names>K</given-names></name><name><surname>Saitoh</surname> <given-names>Y</given-names></name><name><surname>Minami</surname> <given-names>T</given-names></name><name><surname>Takeno</surname> <given-names>N</given-names></name><name><surname>Tsuneyama</surname> <given-names>K</given-names></name><name><surname>Miyahara</surname> <given-names>T</given-names></name><name><surname>Nakayama</surname> <given-names>T</given-names></name><name><surname>Sakurai</surname> <given-names>H</given-names></name><name><surname>Takano</surname> <given-names>Y</given-names></name><name><surname>Nishimura</surname> <given-names>M</given-names></name><name><surname>Imai</surname> <given-names>T</given-names></name><name><surname>Yoshie</surname> <given-names>O</given-names></name><name><surname>Saiki</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption</article-title><source>The Journal of Immunology</source><volume>183</volume><fpage>7825</fpage><lpage>7831</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803627</pub-id><pub-id pub-id-type="pmid">19923448</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotani</surname> <given-names>M</given-names></name><name><surname>Kikuta</surname> <given-names>J</given-names></name><name><surname>Klauschen</surname> <given-names>F</given-names></name><name><surname>Chino</surname> <given-names>T</given-names></name><name><surname>Kobayashi</surname> <given-names>Y</given-names></name><name><surname>Yasuda</surname> <given-names>H</given-names></name><name><surname>Tamai</surname> <given-names>K</given-names></name><name><surname>Miyawaki</surname> <given-names>A</given-names></name><name><surname>Kanagawa</surname> <given-names>O</given-names></name><name><surname>Tomura</surname> <given-names>M</given-names></name><name><surname>Ishii</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Systemic circulation and bone recruitment of osteoclast precursors tracked by using fluorescent imaging techniques</article-title><source>The Journal of Immunology</source><volume>190</volume><fpage>605</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201345</pub-id><pub-id pub-id-type="pmid">23241888</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Hong</surname> <given-names>S</given-names></name><name><surname>Qian</surname> <given-names>J</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Yi</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells</article-title><source>Blood</source><volume>116</volume><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-11-255026</pub-id><pub-id pub-id-type="pmid">20304810</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>JY</given-names></name><name><surname>Tawfeek</surname> <given-names>H</given-names></name><name><surname>Bedi</surname> <given-names>B</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Adams</surname> <given-names>J</given-names></name><name><surname>Gao</surname> <given-names>KY</given-names></name><name><surname>Zayzafoon</surname> <given-names>M</given-names></name><name><surname>Weitzmann</surname> <given-names>MN</given-names></name><name><surname>Pacifici</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand</article-title><source>PNAS</source><volume>108</volume><fpage>768</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1073/pnas.1013492108</pub-id><pub-id pub-id-type="pmid">21187391</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madel</surname> <given-names>MB</given-names></name><name><surname>Ibáñez</surname> <given-names>L</given-names></name><name><surname>Rouleau</surname> <given-names>M</given-names></name><name><surname>Wakkach</surname> <given-names>A</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A novel reliable and efficient procedure for purification of mature osteoclasts allowing functional assays in mouse cells</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2567</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02567</pub-id><pub-id pub-id-type="pmid">30450105</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madel</surname> <given-names>M-B</given-names></name><name><surname>Ibáñez</surname> <given-names>L</given-names></name><name><surname>Wakkach</surname> <given-names>A</given-names></name><name><surname>de Vries</surname> <given-names>TJ</given-names></name><name><surname>Teti</surname> <given-names>A</given-names></name><name><surname>Apparailly</surname> <given-names>F</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immune function and diversity of osteoclasts in normal and pathological conditions</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>01408</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01408</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname> <given-names>A</given-names></name><name><surname>Anginot</surname> <given-names>A</given-names></name><name><surname>Mancini</surname> <given-names>SJ</given-names></name><name><surname>Schiff</surname> <given-names>C</given-names></name><name><surname>Carle</surname> <given-names>GF</given-names></name><name><surname>Wakkach</surname> <given-names>A</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Osteoclast activity modulates B-cell development in the bone marrow</article-title><source>Cell Research</source><volume>21</volume><fpage>1102</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1038/cr.2011.21</pub-id><pub-id pub-id-type="pmid">21321604</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname> <given-names>A</given-names></name><name><surname>Abou-Ezzi</surname> <given-names>G</given-names></name><name><surname>Sitnicka</surname> <given-names>E</given-names></name><name><surname>Jacobsen</surname> <given-names>SE</given-names></name><name><surname>Wakkach</surname> <given-names>A</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow</article-title><source>The Journal of Experimental Medicine</source><volume>209</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1084/jem.20110994</pub-id><pub-id pub-id-type="pmid">22351931</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname> <given-names>A</given-names></name><name><surname>Wakkach</surname> <given-names>A</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Emerging roles of osteoclasts in the modulation of bone microenvironment and immune suppression in multiple myeloma</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>954</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00954</pub-id><pub-id pub-id-type="pmid">28848556</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname> <given-names>T</given-names></name><name><surname>Ichinose</surname> <given-names>S</given-names></name><name><surname>Akiyama</surname> <given-names>M</given-names></name><name><surname>Kasahara</surname> <given-names>Y</given-names></name><name><surname>Tachikawa</surname> <given-names>N</given-names></name><name><surname>Nakahama</surname> <given-names>KI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Involvement of CX3CL1 in the migration of osteoclast precursors across osteoblast layer stimulated by Interleukin-1ß</article-title><source>Journal of Cellular Physiology</source><volume>232</volume><fpage>1739</fpage><lpage>1745</lpage><pub-id pub-id-type="doi">10.1002/jcp.25577</pub-id><pub-id pub-id-type="pmid">27579490</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname> <given-names>MM</given-names></name><name><surname>Najafian</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The role of coinhibitory signaling pathways in transplantation and tolerance</article-title><source>Frontiers in Immunology</source><volume>3</volume><elocation-id>47</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2012.00047</pub-id><pub-id pub-id-type="pmid">22566929</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niess</surname> <given-names>JH</given-names></name><name><surname>Adler</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enteric flora expands gut Lamina propria CX3CR1+ dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions</article-title><source>Journal of Immunology</source><volume>184</volume><fpage>2026</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901936</pub-id><pub-id pub-id-type="pmid">20089703</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noonan</surname> <given-names>K</given-names></name><name><surname>Marchionni</surname> <given-names>L</given-names></name><name><surname>Anderson</surname> <given-names>J</given-names></name><name><surname>Pardoll</surname> <given-names>D</given-names></name><name><surname>Roodman</surname> <given-names>GD</given-names></name><name><surname>Borrello</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma</article-title><source>Blood</source><volume>116</volume><fpage>3554</fpage><lpage>3563</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-05-283895</pub-id><pub-id pub-id-type="pmid">20664052</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panek</surname> <given-names>CA</given-names></name><name><surname>Ramos</surname> <given-names>MV</given-names></name><name><surname>Mejias</surname> <given-names>MP</given-names></name><name><surname>Abrey-Recalde</surname> <given-names>MJ</given-names></name><name><surname>Fernandez-Brando</surname> <given-names>RJ</given-names></name><name><surname>Gori</surname> <given-names>MS</given-names></name><name><surname>Salamone</surname> <given-names>GV</given-names></name><name><surname>Palermo</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Differential expression of the fractalkine chemokine receptor (CX3CR1) in human monocytes during differentiation</article-title><source>Cellular &amp; Molecular Immunology</source><volume>12</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/cmi.2014.116</pub-id><pub-id pub-id-type="pmid">25502213</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname> <given-names>R</given-names></name><name><surname>Duggal</surname> <given-names>G</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Irizarry</surname> <given-names>RA</given-names></name><name><surname>Kingsford</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Bray</surname> <given-names>NL</given-names></name><name><surname>Puente</surname> <given-names>S</given-names></name><name><surname>Melsted</surname> <given-names>P</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differential analysis of RNA-seq incorporating quantification uncertainty</article-title><source>Nature Methods</source><volume>14</volume><fpage>687</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4324</pub-id><pub-id pub-id-type="pmid">28581496</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regoli</surname> <given-names>M</given-names></name><name><surname>Bertelli</surname> <given-names>E</given-names></name><name><surname>Gulisano</surname> <given-names>M</given-names></name><name><surname>Nicoletti</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The multifaceted personality of intestinal CX 3 CR1 + macrophages</article-title><source>Trends in Immunology</source><volume>38</volume><fpage>879</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.it.2017.07.009</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname> <given-names>ME</given-names></name><name><surname>Phipson</surname> <given-names>B</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Law</surname> <given-names>CW</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivollier</surname> <given-names>A</given-names></name><name><surname>Mazzorana</surname> <given-names>M</given-names></name><name><surname>Tebib</surname> <given-names>J</given-names></name><name><surname>Piperno</surname> <given-names>M</given-names></name><name><surname>Aitsiselmi</surname> <given-names>T</given-names></name><name><surname>Rabourdin-Combe</surname> <given-names>C</given-names></name><name><surname>Jurdic</surname> <given-names>P</given-names></name><name><surname>Servet-Delprat</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment</article-title><source>Blood</source><volume>104</volume><fpage>4029</fpage><lpage>4037</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-01-0041</pub-id><pub-id pub-id-type="pmid">15308576</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossini</surname> <given-names>V</given-names></name><name><surname>Zhurina</surname> <given-names>D</given-names></name><name><surname>Radulovic</surname> <given-names>K</given-names></name><name><surname>Manta</surname> <given-names>C</given-names></name><name><surname>Walther</surname> <given-names>P</given-names></name><name><surname>Riedel</surname> <given-names>CU</given-names></name><name><surname>Niess</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CX3CR1⁺ cells facilitate the activation of CD4 T cells in the colonic Lamina propria during antigen-driven colitis</article-title><source>Mucosal Immunology</source><volume>7</volume><fpage>533</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/mi.2013.70</pub-id><pub-id pub-id-type="pmid">24129164</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>JY</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname> <given-names>O</given-names></name><name><surname>Jaensson</surname> <given-names>E</given-names></name><name><surname>Persson</surname> <given-names>EK</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Worbs</surname> <given-names>T</given-names></name><name><surname>Agace</surname> <given-names>WW</given-names></name><name><surname>Pabst</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Intestinal CD103<sup>+</sup>, but not CX3CR1<sup>+</sup>, antigen sampling cells migrate in lymph and serve classical dendritic cell functions</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>3101</fpage><lpage>3114</lpage><pub-id pub-id-type="doi">10.1084/jem.20091925</pub-id><pub-id pub-id-type="pmid">20008524</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeling</surname> <given-names>M</given-names></name><name><surname>Hillenhoff</surname> <given-names>U</given-names></name><name><surname>David</surname> <given-names>JP</given-names></name><name><surname>Schett</surname> <given-names>G</given-names></name><name><surname>Tuckermann</surname> <given-names>J</given-names></name><name><surname>Lux</surname> <given-names>A</given-names></name><name><surname>Nimmerjahn</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inflammatory monocytes and fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice</article-title><source>PNAS</source><volume>110</volume><fpage>10729</fpage><lpage>10734</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301001110</pub-id><pub-id pub-id-type="pmid">23754379</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Tan</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>W</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Guan</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially <italic>via</italic> FABP4 upregulation</article-title><source>The FASEB Journal</source><volume>32</volume><fpage>3215</fpage><lpage>3228</lpage><pub-id pub-id-type="doi">10.1096/fj.201600825RRR</pub-id><pub-id pub-id-type="pmid">29401617</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname> <given-names>YT</given-names></name><name><surname>Cho</surname> <given-names>SF</given-names></name><name><surname>Anderson</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>1822</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01822</pub-id><pub-id pub-id-type="pmid">30147691</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarrant</surname> <given-names>TK</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Rampersad</surname> <given-names>RR</given-names></name><name><surname>Esserman</surname> <given-names>D</given-names></name><name><surname>Rothlein</surname> <given-names>LR</given-names></name><name><surname>Timoshchenko</surname> <given-names>RG</given-names></name><name><surname>McGinnis</surname> <given-names>MW</given-names></name><name><surname>Fitzhugh</surname> <given-names>DJ</given-names></name><name><surname>Patel</surname> <given-names>DD</given-names></name><name><surname>Fong</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Decreased Th17 and antigen-specific humoral responses in CX₃ CR1-deficient mice in the collagen-induced arthritis model</article-title><source>Arthritis &amp; Rheumatism</source><volume>64</volume><fpage>1379</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1002/art.34320</pub-id><pub-id pub-id-type="pmid">22144035</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukamoto</surname> <given-names>M</given-names></name><name><surname>Imai</surname> <given-names>K</given-names></name><name><surname>Ishimoto</surname> <given-names>T</given-names></name><name><surname>Komohara</surname> <given-names>Y</given-names></name><name><surname>Yamashita</surname> <given-names>YI</given-names></name><name><surname>Nakagawa</surname> <given-names>S</given-names></name><name><surname>Umezaki</surname> <given-names>N</given-names></name><name><surname>Yamao</surname> <given-names>T</given-names></name><name><surname>Kitano</surname> <given-names>Y</given-names></name><name><surname>Miyata</surname> <given-names>T</given-names></name><name><surname>Arima</surname> <given-names>K</given-names></name><name><surname>Okabe</surname> <given-names>H</given-names></name><name><surname>Baba</surname> <given-names>Y</given-names></name><name><surname>Chikamoto</surname> <given-names>A</given-names></name><name><surname>Ishiko</surname> <given-names>T</given-names></name><name><surname>Hirota</surname> <given-names>M</given-names></name><name><surname>Baba</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PD ‐L1 expression enhancement by infiltrating macrophage‐derived tumor necrosis factor‐α leads to poor pancreatic cancer prognosis</article-title><source>Cancer Science</source><volume>110</volume><fpage>310</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1111/cas.13874</pub-id><pub-id pub-id-type="pmid">30426611</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucci</surname> <given-names>M</given-names></name><name><surname>Ciavarella</surname> <given-names>S</given-names></name><name><surname>Strippoli</surname> <given-names>S</given-names></name><name><surname>Brunetti</surname> <given-names>O</given-names></name><name><surname>Dammacco</surname> <given-names>F</given-names></name><name><surname>Silvestris</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro</article-title><source>Experimental Hematology</source><volume>39</volume><fpage>773</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2011.04.006</pub-id><pub-id pub-id-type="pmid">21569821</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varol</surname> <given-names>C</given-names></name><name><surname>Vallon-Eberhard</surname> <given-names>A</given-names></name><name><surname>Elinav</surname> <given-names>E</given-names></name><name><surname>Aychek</surname> <given-names>T</given-names></name><name><surname>Shapira</surname> <given-names>Y</given-names></name><name><surname>Luche</surname> <given-names>H</given-names></name><name><surname>Fehling</surname> <given-names>HJ</given-names></name><name><surname>Hardt</surname> <given-names>WD</given-names></name><name><surname>Shakhar</surname> <given-names>G</given-names></name><name><surname>Jung</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Intestinal Lamina propria dendritic cell subsets have different origin and functions</article-title><source>Immunity</source><volume>31</volume><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.06.025</pub-id><pub-id pub-id-type="pmid">19733097</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakkach</surname> <given-names>A</given-names></name><name><surname>Mansour</surname> <given-names>A</given-names></name><name><surname>Dacquin</surname> <given-names>R</given-names></name><name><surname>Coste</surname> <given-names>E</given-names></name><name><surname>Jurdic</surname> <given-names>P</given-names></name><name><surname>Carle</surname> <given-names>GF</given-names></name><name><surname>Blin-Wakkach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts</article-title><source>Blood</source><volume>112</volume><fpage>5074</fpage><lpage>5083</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-01-132787</pub-id><pub-id pub-id-type="pmid">18768394</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Hu</surname> <given-names>Y-Q</given-names></name><name><surname>Zhao</surname> <given-names>Z-J</given-names></name><name><surname>Zhang</surname> <given-names>H-Y</given-names></name><name><surname>Gao</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>W-G</given-names></name><name><surname>Xu</surname> <given-names>X-L</given-names></name><name><surname>Lin</surname> <given-names>X-S</given-names></name><name><surname>Wang</surname> <given-names>J-P</given-names></name><name><surname>Jie</surname> <given-names>Q</given-names></name><name><surname>Luo</surname> <given-names>Z-J</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Screening and validation of serum protein biomarkers for early postmenopausal osteoporosis diagnosis</article-title><source>Molecular Medicine Reports</source><volume>16</volume><fpage>8427</fpage><lpage>8433</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.7620</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitzmann</surname> <given-names>MN</given-names></name><name><surname>Pacifici</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Estrogen deficiency and bone loss: an inflammatory tale</article-title><source>Journal of Clinical Investigation</source><volume>116</volume><fpage>1186</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1172/JCI28550</pub-id><pub-id pub-id-type="pmid">16670759</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname> <given-names>N</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Ginhoux</surname> <given-names>F</given-names></name><name><surname>Randolph</surname> <given-names>GJ</given-names></name><name><surname>Merad</surname> <given-names>M</given-names></name><name><surname>Ding</surname> <given-names>Y</given-names></name><name><surname>Bromberg</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Functional specialization of islet dendritic cell subsets</article-title><source>The Journal of Immunology</source><volume>188</volume><fpage>4921</fpage><lpage>4930</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1103725</pub-id><pub-id pub-id-type="pmid">22508930</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yona</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>K-W</given-names></name><name><surname>Wolf</surname> <given-names>Y</given-names></name><name><surname>Mildner</surname> <given-names>A</given-names></name><name><surname>Varol</surname> <given-names>D</given-names></name><name><surname>Breker</surname> <given-names>M</given-names></name><name><surname>Strauss-Ayali</surname> <given-names>D</given-names></name><name><surname>Viukov</surname> <given-names>S</given-names></name><name><surname>Guilliams</surname> <given-names>M</given-names></name><name><surname>Misharin</surname> <given-names>A</given-names></name><name><surname>Hume</surname> <given-names>DA</given-names></name><name><surname>Perlman</surname> <given-names>H</given-names></name><name><surname>Malissen</surname> <given-names>B</given-names></name><name><surname>Zelzer</surname> <given-names>E</given-names></name><name><surname>Jung</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis</article-title><source>Immunity</source><volume>38</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.12.001</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname> <given-names>MD</given-names></name><name><surname>Wakefield</surname> <given-names>MJ</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Oshlack</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gene ontology analysis for RNA-seq: accounting for selection Bias</article-title><source>Genome Biology</source><volume>11</volume><elocation-id>R14</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2010-11-2-r14</pub-id><pub-id pub-id-type="pmid">20132535</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Hoffmann</surname> <given-names>K</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Förster</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Neonatal lymph node stromal cells drive myelodendritic lineage cells into a distinct population of CX3CR1+CD11b+F4/80+ regulatory macrophages in mice</article-title><source>Blood</source><volume>119</volume><fpage>3975</fpage><lpage>3986</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-06-359315</pub-id><pub-id pub-id-type="pmid">22403256</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54493.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Vunjak-Novakovic</surname><given-names>Gordana</given-names></name><role>Reviewing Editor</role><aff><institution>Columbia University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The authors studied the heterogeneity of inflammatory osteoclasts (i-OCL) using Cx3cr1 as a marker of osteoclast heterogeneity in a mouse model of OVX-induced bone resorption. Cx3cr1-neg OCLs showed higher capacity for bone matrix dissolution, phagocytosed less OVA antigen, and had higher capacity to induce T cell proliferation in vitro, compared to Cx3cr1+ OCLs.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Dissecting the phenotypic and functional heterogeneity of inflammatory osteoclasts by the expression of CX3CR1&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kathryn Cheah as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The conclusions rely on (1) gene expression profiling of sorted CX3CR1+ and CX3CR1- cells, and (2) in vitro culture followed by functional analysis of said sorted cells. However, for these in vitro experiments, the culture conditions employed prior to analysis are not clear. The Materials and methods section suggests that there was extensive culture and stimulation prior to analysis following sorting, but these conditions are not explicitly stated in the main text. If cells were extensively cultured with stimulating cytokines prior to functional analysis, then this would be expected to drastically change their functional profile compared to cells sorted directly from the in vivo environment. This would affect the results in Figures 2, 4, 5, and 6.</p><p>2) While Cx3cr1+ and Cx3cr1- cells have different effects on T cell proliferation, that doesn't necessarily mean that one regulates the activity of the other in vivo. To make this conclusion it would be necessary to deplete selectively one population in vivo and observe the effects on the other population.</p><p>3) Given that macrophages can fuse into multinucleated cells and that Cx3cr1 is a marker of macrophage heterogeneity, it has not been demonstrated that the cells were indeed OCLs and not macrophages. Evidence of the cell identity, OCL or macrophage should be provided.</p><p>4) The absence of Cx3cr1 in Cx3cr1 gfp/gfp mice resulted in reduced recruitment of dendritic cells and Ly6C-hi monocytes to the sites of bone resorption in OVX animals. This result would be expected because Cx3cr1 is well known to be involved in leukocyte trafficking. The authors concluded that this result shows that Ly6C-hi monocytes are progenitors of inflammatory OCLs. This conclusion is not supported by the results.</p><p>5) The authors conclude that Cx3cr1+ cells express higher levels of immunosuppressive genes compared to Cx3cr1- cells. Because the list of genes clearly includes many genes that are immunostimulatory (IL1b, CCL5, Nfkb1, Ccl2, Cd80, CD86), the conclusions about immunosuppressive gene expression profile in Cx3cr1- cells are not clearly supported.</p><p>6) In Figure 1 the authors claim that CXC3R1 positive osteoclasts are needed for the full bone resorbing activity of osteoclasts after ovariectomy. The claim is based on only minor differences and whether CXC3R1 positive osteoclasts were preset or not, the osteoporosis phenotype develops in an equally severe manner. Moreover, these data contradict a statement made later in the paper that CXC3R1 positive osteoclasts are not needed for bone resorption.</p><p>7) Data shown in Figure 2 (no difference in the bone resorption capacities of CX3CR1+ cells isolated from GFP/+ mice and CX3CR1- cells isolated from GFP/GFP mice) and those shown in Figure 4 (large differences in bone resorptive capacities of CX3CR1+ and CX3CR1-negative cells derived from dendricytes) are contradictory. This inconsistency calls into question the validity of using cells derived from the dendricytes in culture if they behave differently from the mature cells isolated from the genetically modified mice.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54493.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The conclusions rely on (1) gene expression profiling of sorted CX3CR1+ and CX3CR1- cells, and (2) in vitro culture followed by functional analysis of said sorted cells. However, for these in vitro experiments, the culture conditions employed prior to analysis are not clear. The Materials and methods section suggests that there was extensive culture and stimulation prior to analysis following sorting, but these conditions are not explicitly stated in the main text. If cells were extensively cultured with stimulating cytokines prior to functional analysis, then this would be expected to drastically change their functional profile compared to cells sorted directly from the in vivo environment. This would affect the results in Figures 2, 4, 5, and 6.</p></disp-quote><p>The reviewers raised an important point. We generated in vitro inflammatory OCLs in the presence of RANK-L and M-CSF, the 2 main osteoclastogenic factors, according to the gold standard protocol for in vitro osteoclastogenesis and starting from their known progenitors, BM-derived dendritic cells (Ibanez et al., 2016). Of course, we agree that investigating osteoclast function on <italic>ex-vivo</italic> isolated osteoclasts would have been the best approach. However, up to now, there are no publications investigating osteoclast function on murine ex vivo-isolated osteoclasts. These cells are rare and firmly attached to the bone and to date there's no procedure in the literature to isolate them in sufficient number to perform subsequent analysis. Consequently, functional assays on osteoclasts always use in vitro-generated cells and much of osteoclast biology described so far in the literature has been investigated in such conditions (Madel et al., 2018). Moreover, at the moment there is no marker to distinguish between inflammatory and tolerogenic Cx3cr1<sup>neg</sup> osteoclasts, which make it impossible to sort them ex vivo. Up to know, the only way to obtain these cells is to differentiate them from their respective known progenitors. Of course, we agree with the reviewers that this may affect their function, but to the same extend as in all studies investigating osteoclast activity and published so far and we don't have any other option.</p><p>To make the procedure of osteoclast preparation clearer as requested, we revised the main text and included more details in the Results and Materials and methods sections as well as in the figure legends. We also added in Figure 2 and Figure 3 a schematic representation of osteoclast preparation.</p><disp-quote content-type="editor-comment"><p>2) While Cx3cr1+ and Cx3cr1- cells have different effects on T cell proliferation, that doesn't necessarily mean that one regulates the activity of the other in vivo. To make this conclusion it would be necessary to deplete selectively one population in vivo and observe the effects on the other population.</p></disp-quote><p>The reviewers are perfectly right and demonstrating the interaction between the 2 i-OCLs subsets in vivo would require specific depletion in vivo of one of these subsets. We are currently investigating in more details the heterogeneity of the different OCL subsets in order to identify suitable factors that would allow to specifically target one or the other OCL subset. This study, and in particular the validation of markers, requires time and the data will be published in a future manuscript.</p><p>However, to address the reviewer's concern and to avoid any over-interpretation of our results, in the revised manuscript we softened our conclusion and clearly stated that the mechanisms we described are only shown in vitro and remain to be demonstrated in vivo.</p><disp-quote content-type="editor-comment"><p>3) Given that macrophages can fuse into multinucleated cells and that Cx3cr1 is a marker of macrophage heterogeneity, it has not been demonstrated that the cells were indeed OCLs and not macrophages. Evidence of the cell identity, OCL or macrophage should be provided.</p></disp-quote><p>To prove the identity of the cells we are analyzing, we performed additional experiments as requested. In particular, because in our protocol osteoclasts are generated in the presence of RANK-L but also M-CSF, a potent inducer of macrophages, we compared these osteoclasts to macrophages generated from bone marrow cells in the presence of M-CSF. In these conditions, we didn't observed cell fusion in macrophages. Moreover, our results showed that while BM-derived macrophages express the 2 BM macrophage markers CD68 and CD169 but are negative for TRAcP expression (Figure 4—figure supplement 1), both Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> subsets of OCLs do not express these macrophage markers but share osteoclast hallmarks, such as TRAcP expression and resorption capacity (Figure 4C-F). These data were included in the revised manuscript and confirm that the cells we are analyzing are <italic>bona fide</italic> OCLs, whether they express or not Cx3cr1.</p><disp-quote content-type="editor-comment"><p>4) The absence of Cx3cr1 in Cx3cr1 gfp/gfp mice resulted in reduced recruitment of dendritic cells and Ly6C-hi monocytes to the sites of bone resorption in OVX animals. This result would be expected because Cx3cr1 is well known to be involved in leukocyte trafficking. The authors concluded that this result shows that Ly6C-hi monocytes are progenitors of inflammatory OCLs. This conclusion is not supported by the results.</p></disp-quote><p>Ly6C<sup>hi</sup> monocytes are involved in osteoclastogenesis in particular in conditions related to inflammatory bone destruction (Seeling et al., 2013; Ammari et al., 2018; Madel et al., 2019), which suggest that they could be progenitors of Cx3cr1<sup>+</sup> osteoclasts that are also associated to the same conditions (Ibanez et al., 2016). To address the capacity of Ly6C<sup>hi</sup> monocytes to differentiate into Cx3cr1<sup>+</sup> osteoclasts, we sorted Ly6C<sup>hi</sup> monocytes from the blood of WT <italic>Cx3cr1</italic><sup>GFP/+</sup> mice and cultured them with M-CSF and RANKL for 6 days as shown in Figure 1—figure supplement 1A. We analyzed the resulting osteoclasts by FACS and found that about 35% of these osteoclasts are GFP/Cx3cr1<sup>+</sup> (Figure 1—figure supplement 1B) demonstrating that Ly6C<sup>hi</sup> monocytes are indeed progenitors of Cx3cr1<sup>+</sup> osteoclasts, which support our conclusion. To make this point more visible and clearer in the revised version of the manuscript, we modified the text in the Results section and added a schematic representation of the experiment (Figure 1—figure supplement 1A).</p><disp-quote content-type="editor-comment"><p>5) The authors conclude that Cx3cr1+ cells express higher levels of immunosuppressive genes compared to Cx3cr1- cells. Because the list of genes clearly includes many genes that are immunostimulatory (IL1b, CCL5, Nfkb1, Ccl2, Cd80, CD86), the conclusions about immunosuppressive gene expression profile in Cx3cr1- cells are not clearly supported.</p></disp-quote><p>There might be a typo error (Cx3cr1- instead of Cx3cr1+) in the last sentence of the reviewer's comment because we only discussed the immunosuppressive capacity of Cx3cr1<sup>+</sup> cells, not of Cx3cr1<sup>neg</sup> cells.</p><p>The reviewers are perfectly right and Cx3cr1<sup>+</sup> osteoclasts do not only express high levels of immunosuppressive genes but also of genes involved in inflammation (Figure 6A), which is in line with their capacity to stimulate to some extend the proliferation of inflammatory CD4<sup>+</sup> T cell (Figure 5G, Figure 5—figure supplement 1). Thus, we agree that just the RNA expression profile of these OCLs is not fully supporting their immunosuppressive role. In the revised manuscript, the comment on the RNAseq analysis for this figure in the Results section has been rephrased accordingly. However, our conclusions do not only rely on the expression profile of osteoclasts, but also on in vitro functional analysis that clearly show:</p><p>1) that the T cell activation capacity of Cx3cr1<sup>+</sup> OCLs is increased when blocking the immunosuppressive checkpoint protein PD1 in vitro (Figure 6C), 2) that in an immunosuppressive assay, Cx3cr1<sup>+</sup> OCLs reduce the capacity of Cx3cr1<sup>neg</sup> OCLs to stimulate T cell proliferation (Figure 6D-E) which is a clear functional demonstration of their immunosuppressive effect, at least in vitro as mentioned in the revised version.</p><disp-quote content-type="editor-comment"><p>6) In Figure 1 the authors claim that CXC3R1 positive osteoclasts are needed for the full bone resorbing activity of osteoclasts after ovariectomy. The claim is based on only minor differences and whether CXC3R1 positive osteoclasts were preset or not, the osteoporosis phenotype develops in an equally severe manner. Moreover, these data contradict a statement made later in the paper that CXC3R1 positive osteoclasts are not needed for bone resorption.</p></disp-quote><p>We agree that the differences observed when comparing OVX WT mice and OVX Cx3cr1-deficient mice (Figure 1B-C) for the microscanner analysis are minor but they are significant and are further supported by a reduced osteoclast number (Figure 1D). But to follow the reviewer concern, we rephrased the comment of this figure in the Results section to indicate this low degree of variation.</p><p>However, there might be a misunderstanding as we didn't claim that Cx3cr1<sup>+</sup> OCLs are required for bone loss in OVX mice. Figure 1 is not addressing the role of Cx3cr1<sup>+</sup> osteoclasts but the implication of the Cx3cr1 protein in bone destruction associated to ovariectomy, which are 2 different questions. In Figure 1, we showed that Cx3cr1, as a protein, is important for the recruitment of OCL progenitors in the bone marrow of OVX mice (Figure 1E-F). Moreover, we showed that i-OCLs from Cx3cr1-deficient and from WT mice have the same resorption activity (Figure 2C), which demonstrates that the protein Cx3cr1 is not important for this activity.</p><p>Moreover, we didn't claim that Cx3cr1<sup>+</sup> OCLs are not needed for bone resorption, we only showed that they resorb less than the Cx3cr1<sup>neg</sup> OCLs (Figure 4E-F).</p><p>But to avoid any misunderstanding, we modified the text to make it clearer and to describe in more details the mouse model we used. We also added in Figure 2 and 3 a schematic representation of the preparation of the cells to avoid any confusion.</p><disp-quote content-type="editor-comment"><p>7) Data shown in Figure 2 (no difference in the bone resorption capacities of CX3CR1+ cells isolated from GFP/+ mice and CX3CR1- cells isolated from GFP/GFP mice) and those shown in Figure 4 (large differences in bone resorptive capacities of CX3CR1+ and CX3CR1-negative cells derived from dendricytes) are contradictory. This inconsistency calls into question the validity of using cells derived from the dendricytes in culture if they behave differently from the mature cells isolated from the genetically modified mice.</p></disp-quote><p>As explained in the first point above, due to methodological issues, in particular the absence of a protocol to isolate sufficient osteoclasts or to sort ex vivo specific subsets of OCLs, there is no other possibility to investigate the function of these OCLs than the use of in vitro differentiated cells. In particular in our study, all inflammatory osteoclasts used in functional assays were derived from dendritic cells in exactly the same culture conditions, as already described (Ibanez et al., 2016). Thus, even if we cannot exclude that the culture conditions could affect osteoclast function compared to in vivo, it would be to the same extend in all our analysis. It would also be to the same extend as in all studies investigating osteoclast activity published so far.</p><p>Regarding the reviewer's concern on potential inconsistency in our results, there might be a misunderstanding. In Figure 2, we addressed the role of Cx3cr1, as a protein, in bone resorption and T cell activation by osteoclasts. This was achieved comparing Cx3cr1<sup>+</sup> osteoclasts coming either from WT (Cx3cr1<sup>GFP/+</sup>) mice or from mice baring a non-functional Cx3cr1 gene (Cx3cr1<sup>GFP/GFP</sup>). There are no data on Cx3cr1<sup>neg</sup> cells in Figure 2. And indeed, we showed that Cx3cr1<sup>+</sup> cells have equivalent resorption capacity whether Cx3cr1 is functional or not (Figure 2), which demonstrates that the protein Cx3cr1 is not important for this activity.</p><p>In contrast, in Figure 4, we addressed, in WT mice, the specific function of the 2 distinct subsets of osteoclasts that are identified using Cx3cr1 as a membrane marker. We showed that Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCLs from WT mice differ in their resorption and T cell activation capacity (Figures 3-6).</p><p>Thus, Figures 1-2 and Figures 3-6 explore 2 completely distinct aspects that could not be compared.</p><p>Importantly, Cx3cr1<sup>+</sup> OCLs having a non-functional <italic>Cx3cr1</italic> gene could not be considered equivalent to Cx3cr1<sup>neg</sup> OCLs from WT mice. Indeed, as shown in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>, principal component analysis of our transcriptomic data clearly demonstrated that while Cx3cr1<sup>+</sup> i-OCLs from WT and mutant mice are closely related, both differ considerably from Cx3cr1<sup>neg</sup> cells from WT mice as they cluster in 2 completely distinct groups (panel A). This was further confirmed by matrix similarity analysis of our transcriptomic data that showed again that the 2 populations are distinct (panel B). Therefore none of the conclusions made for one of these population can be applied to the other.</p><p>However, we recognize that switching from the analysis of the implication of the Cx3cr1 protein in bone loss to the analysis of the respective role of Cx3cr1<sup>+</sup> and Cx3cr1<sup>neg</sup> i-OCL could be confusing. Thus, in the revised manuscript we modified the text to make it clearer and we added schematic representations of the preparation of OCLs in the figures.</p><fig id="sa2fig1"><label>Author response image 1.</label><caption><title>Cx3cr1<sup>neg</sup> i-OCLs from Cx3cr1<sup>GFP/+</sup> mice are distinct from Cx3cr1<sup>+</sup> i-OCLs from deficient Cx3cr1<sup>GFP/GFP</sup> mice.</title><p>A) Principal component analysis of Cx3cr1<sup>+</sup> from deficient Cx3cr1<sup>GFP/GFP</sup> mice (green) and Wt Cx3cr1<sup>GFP/+</sup> mice (red) and Cx3cr1<sup>neg</sup> i-OCLs from Cx3cr1<sup>GFP/+</sup> mice (blue). Data shows the two first components after batch correction. Each dot represents the expression profile of one sample. B) Similarity matrix analysis on the same samples.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54493-resp-fig1-v1.tif"/></fig></body></sub-article></article>